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ABSTRACT 
The human coronavirus NL63 was discovered in 2004 by a team of researchers in Amsterdam. 
Since its discovery it has been shown to have worldwide spread and affects mainly children, 
aged 0-5 years old, the immunocompromised and the elderly. Infection with HCoV-NL63 
commonly results in mild upper respiratory tract infections and presents as the common cold, 
with symptoms including fever, cough, sore throat and rhinorrhoea. Lower respiratory tract 
findings are less common but may develop into more serious complications including 
bronchiolitis, pneumonia and croup. 
 The primary function of the HCoV-NL63 nucleocapsid (N) protein is the formation of the 
protective ribonucleocapsid core. For this particle to assemble, the N-protein undergoes N-N 
dimerization and then interacts with viral RNA. Besides the primary structural role of the N-
protein, it is also understood to be involved in viral RNA transcription, translation and 
replication, including several other physiological functions. The N-protein is also highly 
antigenic and elicits a strong immune response in infected patients. For this reason the N-protein 
may serve as a target for the development of diagnostic assays. 
 We have used bioinformatic analysis to analyze the HCoV-NL63 N-protein and 
compared it to coronavirus N-homologues. This bioinformatic analysis provided the data to 
generate recombinant clones for expression in a bacterial system. We constructed recombinant 
clones of the N-protein of SARS-CoV and HCoV-NL63 and synthesized truncated clones 
corresponding to the N- and C-terminal of the HCoV-NL63 N-protein. These heterologously 
expressed proteins will serve the basis for several post-expression studies including 
characterizing the immunogenic epitope of the N-protein as well identifying any antibody cross-
reactivity between coronavirus species.  
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Introduction 
Coronaviruses (CoVs) were first identified in 1937, when the virus responsible for infectious 
bronchitis in chickens was isolated from chick embryos (Beaudette and Hudson 1937). Several 
other animal coronaviruses were later identified in the 1940s with the discovery of mouse 
hepatitis virus (MHV) (Cheever, Daniels et al. 1949) and transmissible gastroenteritis virus 
(TGEV) in pigs (Doyle and Hutchings 1946). The first human coronaviruses were identified in 
the 1960s by Tyrell and Bynoe who passaged a virus, named B814, in human embryonic 
tracheal organ cultures. When this virus was inoculated intranasally into human volunteers, 
common cold-like symptoms were produced (Tyrrell and Bynoe 1965; Tyrrell and Bynoe 
1966). Hamre and Procknow (1966) later isolated a virus, which they were able to grow in 
tissue culture, from medical students also presenting with symptoms of the common cold. The 
virus was later named human coronavirus 229E (HCoV-229E) (Hamre and Procknow 1966).  
It was shown that all of these viruses were ether-sensitive, indicating the presence of a 
lipid covering. McIntosh et al. (1967) were then able to recover several ether-sensitive viruses 
in organ culture which were termed “OC” viruses to indicate passage in organ culture. Under 
electron microscopy all of these viruses had morphologies similar to several other animal 
viruses previously identified, namely infectious bronchitis virus (IBV), MHV and TGEV 
(McIntosh, Dees et al. 1967). These viruses were later classified as coronaviruses, which was 
accepted as a new genus in 1975. Unfortunately, many of the clinical samples collected and 
stored in the 1960s, which were positive for coronavirus-like particles, were subsequently lost. 
Therefore, until the discovery of SARS-CoV in 2003, the study of human coronaviruses was 
restricted to research of HCoV-229E and HCoV-OC43 (McIntosh 2005). 
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CoVs are enveloped viruses and are now placed in the order Nidovirales, along with 
the arteriviruses, toroviruses and roniviruses. The Coronaviridae family is composed of 
single-stranded, positive sense RNA viruses, with the largest known RNA viral genomes, 
ranging in size from 25 to 30 kb (He, Dobie et al. 2004). Traditionally, coronaviruses were 
divided into Group I, II and III based on serological relationships (Figure 1.1). Viruses in 
Groups I and II are known to typically infect mammalian hosts, whereas members of Group III 
infect birds (van der Hoek, Pyrc et al. 2006; Pyrc, Berkhout et al. 2007). The International 
Committee for Taxonomy of Viruses (ICTV) recently proposed that these three groups be 
replaced by three new genera, namely Alphacoronavirus, Betacoronavirus and 
Gammacoronavirus (Woo, Huang et al. 2010). 
Coronaviruses are responsible for a variety of diseases in animals resulting in 
respiratory, enteric, nephritic, hepatic and neurological conditions with a varying degree of 
severity (McIntosh 2005; Lau, Li et al. 2010). In humans, coronaviruses typically result in 
approximately 10-30% of upper respiratory tract infections, which are known to lead to the 
common cold. Until the discovery of the severe acute respiratory syndrome coronavirus 
(SARS-CoV) it was thought that human coronavirus infections were not severe. Infection with 
SARS-CoV however resulted in approximately 10% mortality of infected patients, with 
mortality as high as 40-55% in certain population (Surjit, Kumar et al. 2005) and age (Marra, 
Jones et al. 2003) groups. SARS presents as an atypical pneumonia (He, Dobie et al. 2004; 
Lee, Lee et al. 2008), with pneumocytes being the primary target of infection. Infection results 
in hemorrhagic inflammation in most pulmonary alveoli with alveolar thickening, diffuse 
alveolar damage, desquamation of pneumocytes, formation of hyaline membranes and 
 
 
 
 
Chapter 1 
4 
 
multinucleated pneumocytes with capillary engorgement and microthrombosis (Surjit, Liu et 
al. 2004). 
 
Figure 1.1: Phylogenetic analysis of coronaviruses. Typically, members of Groups I and II coronaviruses infect 
mammalian hosts, where members of Group III infect birds (van der Hoek, Pyrc et al. 2006; Pyrc, Berkhout et al. 
2007). 
 
1. Outbreak of SARS-CoV: Stimulating Coronavirus Research 
In November 2002 an outbreak of atypical pneumonia occurred in Guangdong Province, 
China. From November 2002 to July 2003 a total of 8098 patients were affected by the 
atypical pneumonia resulting in 774 deaths globally. The disease was termed severe acute 
respiratory syndrome and the causative agent was identified as the severe acute respiratory 
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syndrome coronavirus (SARS-CoV) (Drosten, Gunther et al. 2003; Ksiazek, Erdman et al. 
2003; Peiris, Lai et al. 2003). The SARS epidemic was halted in 2003 by a highly effective 
global public health response and SARS-CoV is currently not circulating in the human 
population (Pyrc, Berkhout et al. 2007). SARS-CoV probably originated from a wild animal 
reservoir, most likely bats, and was transmitted in a zoonotic event to humans via infected 
civet cats, which were sold as food in live animal markets in China (van der Hoek, Pyrc et al. 
2006). Interestingly, earlier seroepidemiological studies have shown that 40% of wild animal 
traders and 20% of people responsible for the slaughtering of animals in the region where 
human SARS was thought to originate, were seropositive for SARS-CoV, although all cases 
were asymptomatic. This indicates that these people were previously exposed to a SARS-like 
virus, which resulted in asymptomatic infection (Guan, Zheng et al. 2003). 
Lau et al. (2010) have shown that 10 strains of SARS-related coronaviruses (SARSr-
CoV) in bats undergo frequent recombination. This recombination possibly gave rise to 
SARSr-CoV in civets, which was then transmitted to humans resulting in the outbreak of 
SARS. SARSr-CoVs are currently circulating in animal hosts and reservoirs (Lau, Li et al. 
2010). Up to 39% of all sequenced Group I and II coronaviruses are found in bats, with nearly 
all Group III viruses found in birds. The huge diversity of coronaviruses found in bats and 
birds has indicated that bats possibly provided the gene pools for Group I and II coronaviruses, 
where birds provided the gene pools for Group III viruses (Woo, Lau et al. 2009). The huge 
diversity of coronaviruses found in bats and birds could be due, in part, to the diversity of 
these animals themselves with bats accounting for up to 20% of all mammalian species and 
birds being the most diverse tetrapod vertebrates. The ability to fly and social habits of these 
animals may also promote intra- and interspecies viral spread (Woo, Lau et al. 2009). The 
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coronavirus diversity found in these animals may lead to recombination and generation of new 
coronavirus species, as seen with SARS-CoV.  
Following the outbreak of SARS it was shown that coronaviruses are capable of 
undergoing recombination events resulting in a more lethal form of the virus. This ignited a 
new interest in the detection and characterization of previously unidentified respiratory 
viruses. There are now 5 known human coronaviruses with four currently circulating in the 
human population, namely HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-NL63. 
HCoV-HKU1 was isolated from a 71 year old man presenting with pneumonia. It was 
identified by RT-PCR, however it has posed difficult to characterize due to its inability to be 
cultured in various cell lines (Woo, Lau et al. 2005). 
 
2. HCoV-NL63: A Novel Respiratory Virus 
2.1 Discovery of HCoV-NL63 
In 2003 a 7 month old child presenting with bronchiolitis and conjunctivitis was screened for 
several respiratory viruses to identify the causative agent, with all diagnostics yielding 
negative results. The group led by Lia van der Hoek then used a modified cDNA amplified 
restriction fragment-length polymorphism (cDNA-AFLP) technique (Virus-Discovery-cDNA-
AFLP or VIDISCA), to identify the causative agent. Briefly, the technique utilizes reverse 
transcription-PCR of viral RNA with subsequent restriction digest of the cDNA using 
frequently cutting restriction enzymes. Since the restriction sites are selected and therefore 
known, the resultant “sticky ends” can be ligated into anchors for amplification and 
sequencing with specific primers (Figure 1.2). The results showed highest sequence 
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similarities with known coronaviruses, but with significant sequence divergence indicating the 
discovery of a new coronavirus species, later named human coronavirus NL63 (van der Hoek, 
Pyrc et al. 2004). 
 
Figure 1.2: VIDISCA technique used to identify the new HCoV-NL63. VIDISCA utilizes the restriction of 
cDNA generated by RT-PCR of isolated viral RNA. As the restriction sites are known the digested fragments can 
be amplified with specific primers (van der Hoek, Pyrc et al. 2004). 
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At about the same time, two other independent groups identified essentially the same 
virus (Fouchier, Hartwig et al. 2004; Esper, Weibel et al. 2005). Shortly after the van der 
Hoek paper (van der Hoek, Pyrc et al. 2004), a novel coronavirus that replicated efficiently in 
tertiary monkey kidney and Vero cells, was retrospectively isolated from a nose swab sample 
collected in 1988 from an 8 month-old boy presenting with pneumonia. This virus was 
reported to be similar to HCoV-NL63 and named HCoV-NL (Fouchier, Hartwig et al. 2004). 
Then in 2005, Esper et al. (2005) also reported the identification of a novel coronavirus 
isolated in New Haven, Connecticut, which was named NH. This novel virus was identified by 
PCR which was adapted to amplify a conserved region within the replicase 1a gene (Esper, 
Weibel et al. 2005). Subsequent sequence analysis showed that these three viruses were 
essentially all the same virus or variants thereof (Enserink 2005; Esper, Weibel et al. 2005). 
It is obvious that HCoV-NL63 has been circulating in the human population since 
before 1988 (Fouchier, Hartwig et al. 2004). In fact, molecular clock analyses have shown that 
HCoV-NL63 and HCoV-229E diverged from a most common ancestor approximately 900 
years ago, with HCoV-NL63 later diverging into two lineages with subsequent recombination 
of the two lineages during co-infection. This frequent recombination has given HCoV-NL63 a 
mosaic structured genome (Pyrc, Dijkman et al. 2006). HCoV-NL63 has since been isolated 
and identified in Australia (Arden, Nissen et al. 2005), Japan (Ebihara, Endo et al. 2005), 
Belgium (Moes, Vijgen et al. 2005), France (Vabret, Mourez et al. 2005), Switzerland (Kaiser, 
Regamey et al. 2005), Canada (Bastien, Anderson et al. 2005), Hong Kong (Chiu, Chan et al. 
2005), Italy (Minosse, Selleri et al. 2008), Germany and South Africa (Smuts 2008; Venter, 
Lassauniere et al. 2011), to name a few, which indicates a global spread of this virus (van der 
Hoek, Pyrc et al. 2006). 
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2.2 Clinical Findings and Prevalence of HCoV-NL63 
HCoV-NL63 has been shown to affect both the upper and lower respiratory tract and often 
presents clinically as the common cold. Symptoms have been found to be similar to those of 
infection with HCoV-229E and HCoV-OC43 (Abdul-Rasool and Fielding 2010). Mild 
symptoms affecting the upper respiratory tract include fever, cough, sore throat and 
rhinorrhoea, with more serious lower respiratory tract complications including bronchiolitis, 
pneumonia and croup (van der Hoek, Sure et al. 2005; van der Hoek, Pyrc et al. 2006).  
In an isolated case, a patient who underwent allo-haematopoietic cell transplant 
surgery presented with a respiratory prodrome five months after surgery. He presented with a 
dry cough, fever and intercostal pain due to coughing with influenza-like symptoms. The 
disease was most likely contracted from his five year old son who presented with similar 
symptoms a week earlier. Bronchoalveolar lavage, tracheal and nasopharyngeal fluid was 
shown to be negative for fungi, acid-fast bacilli, gram stain and culture, cytology, CMV and 
respiratory viruses including RSV, influenza A and B, parainfluenza virus, metapneumovirus, 
adenovirus and rhinovirus, however, was PCR positive for HCoV-NL63 in bronchoalveolar 
lavage fluid. The patient’s condition worsened and on day four he was intubated and by day 
seven steroid treatment was initiated, without improvement. Five weeks following admission 
to hospital, the patient died as a result of progressive respiratory failure. Post-mortem autopsy 
showed severe alveolar damage with no pathogens, including HCoV-NL63, present, indicating 
that the patient had cleared the virus. These results indicate that routine screening of 
coronaviruses, in particular for HCoV-NL63, should be conducted prior to and following 
transplant surgery. In this case, HCoV-NL63 was shown to result in severe lower respiratory 
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tract infection and disease which, subsequent to clearing of the virus, led to fatality 
(Oosterhof, Christensen et al. 2010). 
Prevalence of infection with HCoV-NL63 is highest in the age group 0-5 years old and 
is also frequently observed in patients who are immunocompromised, as well as the elderly 
(van der Hoek, Pyrc et al. 2006). HCoV-NL63 has been detected in 1.0-9.3% of respiratory 
tract infections in children (Fielding 2011), with 75% of children aged 2.5-3.5 years being 
seropositive for HCoV-NL63 (Dijkman, Jebbink et al. 2008). In the Esper study, 11 patients 
who tested positive for HCoV-NH had been hospitalized since birth, indicating that HCoV-
NH and HCoV-NL63 may represent a nosocomial or congenital infection (Esper, Weibel et al. 
2005). In fact, maternally acquired antibodies are present in newborns and probably provide 
protection against infection. These maternally acquired antibodies usually diminished within 
4-5 months after birth (Shao, Guo et al. 2007; Dijkman, Jebbink et al. 2008). In a 
comprehensive population based study conducted in Germany, it was found that HCoV-NL63 
resulted in infection of 7 per 1000 children per year, which can be extrapolated to 16 929 visits 
to the doctor in Germany alone. Hospitalization rates were much lower with a rate 22 per 100 
000 children, indicating a total of 522 hospitalizations in Germany each year (van der Hoek, 
Ihorst et al. 2010). 
Although HCoV-NL63 infection has been found to occur most frequently during the 
winter months (van der Hoek, Ihorst et al. 2010; Fielding 2011), several reports indicate 
seasonal variations. In China, HCoV-NL63 infections peaked in spring and autumn (Chiu, 
Chan et al. 2005), and in Taiwan, infections peaked during summer (Wu, Chang et al. 2008). 
In Thailand, however, no seasonal variation was identified as HCoV-NL63 could be detected 
throughout the year (Dare, Fry et al. 2007). This may be due, in part, to the tropical climate of 
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Thailand where seasonal changes are not as significant as within temperate climates. The peak 
in seasonal incidence during the winter months may also promote co-infection with other 
respiratory viruses which spike during the same period. This may also promote recombination 
of respiratory viruses which co-infect the same cell. 
The epidemiology of coronaviruses, including HCoV-NL63, remains poorly defined 
due largely to the fact that these viruses are not routinely screened for. Human CoVs are rather 
clinically diagnosed leading to a potentially great underestimation of the role of HCoVs in 
respiratory infections (van Elden, van Loon et al. 2004). The respiratory site chosen for 
sampling also plays a large role in misdiagnosis of respiratory viruses as different results have 
been obtained from nasopharyngeal aspirates and nose/throat swabs (Kleines, Scheithauer et 
al. 2007). Different diagnostic assays used in detection have also been shown to have varying 
degrees of sensitivity leading to further underestimation of these viruses in disease (Fielding 
2011). Therefore, the development of reliable and routine screening methods for HCoVs in 
respiratory infections is of increasing importance in understanding the epidemiology of these 
viruses and the role(s) they play in other diseases.  
 
2.3 Association of HCoV-NL63 with Croup 
Croup is a common manifestation of lower respiratory tract disease and is characterized as an 
inflammation of the trachea which obstructs normal breathing, producing the characteristic 
“barking” cough that usually worsens at night (van der Hoek, Sure et al. 2005). Croup patients 
present with pharyngitis and hospitalization is often required (Fielding 2011). The causal 
agent is generally assumed to be a respiratory virus, with parainfluenza virus 1 (PIV1) and 
influenza A frequently being implicated. Other respiratory viruses associated with croup 
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include rhinovirus, PIV3, respiratory syncytial virus, human bocavirus and several others in a 
small minority of subjects, with co-infections found in 11% of patients (Sung, Lee et al. 
2010).  
An association between HCoV-NL63 and croup has been reported by several 
researchers (Chiu, Chan et al. 2005; van der Hoek, Sure et al. 2005; Wu, Chang et al. 2008; 
Sung, Lee et al. 2010). van der Hoek et al. (2005) reported a strong association between 
HCoV-NL63 and croup, with 43% of HCoV-NL63-positive patients - with single infection 
and high viral load - presenting with croup. Of croup patients, 17.4% tested positive for 
HCoV-NL63, compared to 4.2% of non-croup patients. HCoV-NL63 is therefore the second 
most commonly identified respiratory virus in croup patients. The chance of developing croup 
is in fact 6.6 times higher in HCoV-NL63 positive patients than HCoV-NL63 negative 
patients, suggesting a strong causal relationship (van der Hoek, Sure et al. 2005; Sung, Lee et 
al. 2010). 
 
2.4 Association of HCoV-NL63 with Non-respiratory Findings 
2.4.1 Kawasaki Disease 
Kawasaki disease is one of the most common forms of childhood vasculitis and presents with 
prolonged fever and a polymorphic exanthema, oropharygeal erythema and bilateral 
conjunctivitis (van der Hoek, Pyrc et al. 2006) and may result in aneurysms of coronary 
arteries (Esper, Shapiro et al. 2005). Kawasaki disease has been recognized as the most 
common cause of chronic heart disease in children (Esper, Shapiro et al. 2005). An infective 
agent has long been thought to be the cause of Kawasaki disease because of seasonal peaks, 
focal epidemics and the acute onset of symptoms such as fever, rash, conjuctival infection and 
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cervical adenitis, which resemble other infectious diseases. Since a respiratory syndrome 
precedes symptoms of Kawasaki disease, a respiratory virus has been proposed as the 
causative agent (Bell, Brink et al. 1981). A strong IgA response has also been detected in the 
respiratory tract and medium & large arteries during Kawasaki disease, indicating possible 
entry of a microbe via the respiratory tract (Rowley, Shulman et al. 2000). Furthermore, the 
highest incidence is found in toddlers, with only rare cases in adults and infants, which suggest 
a causative agent to which adults are immune to and from which infants are protected by 
passive immunity. Bacterial and viral cultures and serological investigations, however, have 
yet to identify the causative agent (Shimizu, Shike et al. 2005). The diagnosis of Kawasaki 
disease is based entirely on clinical features and currently no diagnostic tests are available. 
An association between Kawasaki disease and HCoV-NL63 was recently reported by 
Esper et al. (2005). In their study, viral sequences of HCoV-NL63 were detected from 
respiratory secretions for 8 of 11 patients presenting with Kawasaki disease; only 1 of 22 
control subjects were positive for HCoV-NL63 genetic material. These results are indicative 
of a strong association between Kawasaki disease and HCoV-NL63 infection (Esper, Shapiro 
et al. 2005). However, in a separate study by Shimizu et al. (2005) only 1 of 48 respiratory 
secretions from patients suffering from Kawasaki disease was positive for HCoV-NL63. The 
contradiction in these findings may be due to differences in geographical region, definition of 
cases, detection method used or respiratory site sampled. Also, since the Esper study only used 
samples from patients presenting with respiratory symptoms, it was sample biased for a high 
rate of HCoV-NL63 infection (Shimizu, Shike et al. 2005). Several other groups have since 
reported no correlation between HCoV-NL63 infection and Kawasaki disease (Belay, Erdman 
 
 
 
 
Chapter 1 
14 
 
et al. 2005; Ebihara, Endo et al. 2005b; Chang, Chiang et al. 2006; Lehmann, Klar et al. 2009) 
and therefore this association should be approached with a level of caution. 
 
2.4.2 Gastrointestinal Disease 
HCoV-NL63 has been reported to be present in the stool samples of patients with diarrhea, 
indicating a causal role in gastroenteritis (Vabret, Mourez et al. 2005; Leung, Li et al. 2009; 
Risku, Lappalainen et al. 2010). The involvement in gastrointestinal disease is not unique to 
HCoV-NL63, as all non-SARS CoVs have been found in stool samples of children presenting 
with acute gastroenteritis (Risku, Lappalainen et al. 2010). In addition, in several studies a 
relationship was found between SARS-CoV and gastrointestinal disease (Leung, To et al. 
2003; Clark and McKendrick 2004). Involvement of HCoVs in gastrointestinal disease is a 
result of viral invasion of the intestinal mucosa (Principi, Bosis et al. 2010). The majority of 
patients with HCoVs detectable in stool samples, also tested positive for other gastroenteritis 
viruses, including norovirus and rotavirus (Risku, Lappalainen et al. 2010). HCoVs are more 
frequently reported in outpatients than hospitalized patients presenting with gastroenteritis 
(Kheyami, Nakagomi et al. 2010), indicating that gastroenteritis related to HCoV infection 
may possibly be less severe and therefore underrepresented. 
A recent report showed that HCoV-NL63 was detectable in 4 of 878 stool samples 
from patients presenting with gastroenteritis (Risku, Lappalainen et al. 2010). Another report 
however showed that gastroenteritis developed in 33.3% of patients infected with HCoV-
NL63 (Leung, Li et al. 2009). These and other results could indicate that HCoV-NL63, and 
other HCoVs, may have a causal role in gastroenteritis. However, since many HCoV-NL63 
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positive patients present with co-infections with other gastrointestinal viruses, the exact role of 
HCoV-NL63 cannot be identified at this time (Fielding 2011). 
 
2.5 Co-infection of HCoV-NL63 and other respiratory viruses 
As many as half of HCoV-NL63 infections may present as co-infections with another 
respiratory virus including influenza A (Chiu, Chan et al. 2005), respiratory syncytial virus, 
parainfluenza-3 or human metapneumovirus (Arden, Nissen et al. 2005; van der Hoek, Sure et 
al. 2005). HCoV-NL63 presenting as a co-infection is more likely to lead to hospitalization 
than in patients presenting with HCoV-NL63 alone, indicating the increased severity of co-
infections. In patients co-infected with HCoV-NL63 and another respiratory virus, the total 
viral load of HCoV-NL63 is lower. This could indicate that HCoV-NL63 is capable of 
lowering the immune response to allow for a secondary infection, by which time the HCoV-
NL63 infection has subsided or that the secondary infection activates the innate immune 
response thereby inhibiting HCoV-NL63 progression. Other possible reasons for this 
decreased HCoV-NL63 viral load could be that the co-infected viruses compete for the same 
target cell or receptor or that HCoV-NL63 has a prolonged persistence at low levels (van der 
Hoek, Pyrc et al. 2006). The decreased viral load could also be attributed to HCoV-NL63 
being less well adapted to the host compared to the co-infecting respiratory virus. HCoV-
NL63 has also been shown to promote bacterial co-infection by increasing the adherence of 
Streptococcus pneumonia to epithelial cells (Golda, Malek et al. 2011).  
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3. Coronavirus Genome, Transcription and Replication 
Coronaviruses have a positive sense, non-segmented, single stranded RNA genome of 
approximately 30kb, which is typically organized in the conserved order: 5′-replicase (1a, 1b), 
spike (S), envelope (E), membrane (M) and nucleocapsid (N)-3′ (He, Dobie et al. 2004) 
(Figure 1.3). The genome has a 5′cap and is 3′polyadenylated (Pyrc, Berkhout et al. 2007). 
Whereas HCoV-NL63 has one additional open reading frame (ORF) - ORF3 - between the S 
and E ORFs (Pyrc, Jebbink et al. 2004), SARS-CoV has 9 ORFs distributed amongst the 
structural genes. The 5′ two-thirds of the coronavirus genome contain the large 1a and 1b 
ORFs. These ORFs encode proteins necessary for RNA replication and are termed the non-
structural proteins (nsp) (van der Hoek, Pyrc et al. 2006).  
Coronaviruses utilize a discontinuous replication strategy to synthesize its subgenomic 
(sg) mRNA during synthesis of the negative strand from the positive sense genome template 
(Pyrc, Jebbink et al. 2004). The sg mRNA is then copied into a positive sense strand. 
Transcription of the HCoV-NL63 genome produces six distinct mRNAs (Pyrc, Berkhout et al. 
2007), which include the entire RNA genome and a nested set of five sg mRNAs. The six 
mRNAs encode for the 7 ORFs of HCoV-NL63, with ORF3 and S, M, E and N encoded by 
the five subgenomic mRNAs (Pyrc, Jebbink et al. 2004). A transcription regulatory sequence 
of AACUAAA, which is essential for sg mRNA synthesis, is located at the 5′-end of each 
ORF with the exception of ORF-E (Pyrc, Jebbink et al. 2004; Pyrc, Berkhout et al. 2007; 
Sawicki, Sawicki et al. 2007). All positive sense mRNAs also share a leader sequence of 
approximately 70 nucleotides which is identical to the leader sequence of the genomic RNA 
(Pyrc, Jebbink et al. 2004; Sawicki, Sawicki et al. 2007).  
 
 
 
 
 
The Human Coronavirus NL63: A Review 
17 
 
 
Figure 1.3: Organization of the HCoV-NL63 genome (Gene sizes are not to scale). The 5′ two-thirds of the 
HCoV-NL63 genome is comprised of the 1a, 1b replicase gene with the 3′ one-third containing the genes 
encoding for the spike (S), envelope (E), membrane (M) and nucleocapsid (N) structural proteins. A single 
accessory gene, ORF3, is present between the S and E ORF’s (van der Hoek, Pyrc et al. 2006). 
 
The expression of the entire 1ab gene produces two large polyproteins (1a and 1ab), 
where the synthesis of the 1ab polyprotein requires a -1 ribosomal frameshift during 
translation of the 1a gene (Pyrc, Jebbink et al. 2004; Sawicki, Sawicki et al. 2007). With a -1 
ribosomal frame shift, the ribosome is triggered to move one nucleotide upstream to encode a 
completely new protein (Namy, Moran et al. 2006). The process by which a ribosomal 
frameshift occurs is not completely understood, but is triggered by a heptanucleotide 
“slippery” sequence lying upstream of a RNA pseudoknot structure. A RNA pseudoknot is 
comprised of two stem sequences folding back on themselves to form a two loop structure and 
a brief complementary sequence of approximately 17 base pairs (Figure 1.4). The frameshift is 
initiated when the elongating ribosome is stalled by the heptanucleotide sequence followed by 
a frameshift stimulated by the pseudoknot. This most likely occurs by a difference in free 
energy between the folded and partially folded pseudoknot structure which promotes 
frameshifting by increasing the kinetic barrier (Giedroc, Theimer et al. 2000). 
 
 
 
 
Chapter 1 
18 
 
 
Figure 1.4: Structure of an RNA pseudoknot. An RNA pseudoknot is formed by stem A forming loop A which 
folds back on stem B to form a brief complimentary sequence with stem B and A. The complimentary sequence 
folds again to form loop B which rejoins to stem B (Giedroc, Theimer et al. 2000). 
 
The 1a and 1ab polyproteins are subsequently cleaved by viral encoded proteases to 
produce 16nsps. Polyprotein 1a is cleaved to form nsp 1-11, where polyprotein 1ab forms nsp 
12-16. These nsps form the replicase-transcriptase proteins of coronaviruses and assemble, 
along with other viral and host proteins, into a membrane bound replication-transcription 
complex. Previous studies have shown that these proteins have at least 8 enzymatic functions 
including protease, RNA-dependant RNA polymerase and 5′-to-3′ helicase activity (Marra, 
Jones et al. 2003; Sawicki, Sawicki et al. 2007).  
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The 3′ one-third of the genome encodes the structural proteins S, E, M and N, with 
haemagglutinin esterase found in Group II viruses. The accessory proteins, which differ in 
number and position for different coronaviruses, are found in between the structural proteins 
(van der Hoek, Pyrc et al. 2006). The function of these accessory proteins is important in 
determining pathogenesis of coronaviruses as accessory proteins of certain coronaviruses have 
shown to contribute to the progression of the disease (Kopecky-Bromberg, Martinez-Sobrido 
et al. 2007). 
RNA virus genomes have a high mutation rate and therefore the probability of 
generating genetic diversity is high. This mutation rate is estimated to be approximately one 
mutation per replication cycle, and as a consequence, RNA viruses exist as a dynamic 
distribution of variants which closely resemble a master sequence. This high mutation rate 
allows the virus to adapt quickly to environmental changes and pressures (van der Hoek, Pyrc 
et al. 2006). Coronaviruses are also capable of recombination, as with SARS-CoV, if 2 or 
more viruses infect the same cell (Kahn and McIntosh 2005) and as HCoV-NL63 presents 
frequently as a co-infection with other respiratory viruses, this may - although highly unlikely 
- increase the possibility of recombination (Pyrc, Dijkman et al. 2006). 
Nidovirus replication is restricted to the cytoplasm (Rowland, Chauhan et al. 2005) 
and viral attachment to the host cell is mediated by the S protein. The viral membrane 
proteins, including the M- and S-proteins, insert into the endoplasmic reticulum (ER) and 
Golgi intermediate compartment. During this process the full length RNA genome associates 
with the N-protein. The resulting ribonucleoprotein complex then associates with the M-
protein in the membrane of the ER. Viral particles are formed as the nucleocapsid complex 
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buds into the lumen of the ER. The virus then migrates through the Golgi complex and exits 
the cell, most likely via exocytosis (Marra, Jones et al. 2003). 
 
4. HCoV-NL63 Cellular Entry by ACEII 
HCoV-229E, the most closely related human coronavirus to HCoV-NL63, has been shown to 
utilize CD13 (aminopeptidase N) for cellular entry and before the discovery of HCoV-NL63 it 
was thought that all Group I coronaviruses utilize CD13 as a receptor for cellular entry (van 
der Hoek, Pyrc et al. 2006). HCoV-NL63 has, however, been shown to use angiotensin-
converting enzyme (ACE) II for cellular entry, the same receptor for cellular entry as SARS-
CoV.  
ACEII is an important component of the rennin-angiotensin system, which is involved 
in the control of blood pressure (Hofmann, Pyrc et al. 2005). ACE is responsible for activating 
the rennin-angiotensin system by cleaving angiotensin I into angiotensin II, whereas ACEII 
negatively regulates this system by inactivating angiotensin II (Pyrc, Berkhout et al. 2007). 
ACEII molecules are found to be localized to arterial and venous endothelial cells, arterial 
smooth muscle cells and epithelia of small intestines as well as the ciliated cells of human 
nasal and tracheobronchial airway epithelia, thereby explaining the infection of cells of the 
upper airways (van der Hoek, Pyrc et al. 2006; Pyrc, Berkhout et al. 2007). 
The S-glycoproteins of coronaviruses provide the virion with a corona (crown) like 
appearance under electron microscopy and mediates infection of host cells. Entry of 
coronaviruses into the host cell is facilitated either by direct fusion with the plasma membrane 
or by endocytosis and subsequent fusion with the endosomal membrane (Pyrc, Berkhout et al. 
 
 
 
 
The Human Coronavirus NL63: A Review 
21 
 
2007). The amino-terminal of the S-protein contains the receptor-binding domain and the C-
terminal domain contains the membrane anchoring domain with fusogenic function (Pyrc, 
Berkhout et al. 2007). Binding of the S protein to certain receptors on the host cell determines, 
to a large extent, the type of host cell which the virus can infect, which has important 
implications for viral pathogenicity (Hofmann, Pyrc et al. 2005). Hofmann et al. (2005) have 
shown that HCoV-NL63 and SARS-CoV use the same receptor for cellular entry even though 
there is no similarity between the SARS-CoV and HCoV-NL63 S-protein that could explain 
this shared receptor usage. HCoV-NL63 and SARS-CoV must therefore have evolved their 
ability to bind to ACEII separately due to a common “virus-binding hotspot” on ACEII 
(Chatterjee, Johnson et al. 2009). 
This common receptor usage indicates that HCoV-NL63 is able to infect the same host 
cell as SARS-CoV. HCoV-NL63 has however, only been shown to result in mild or moderate 
respiratory symptoms and it is therefore conceivable that HCoV-NL63 lacks a pathogenicity 
factor present in SARS-CoV. It is assumed that this pathogenicity factor could be encoded by 
1 or more of the 9 accessory genes present in the SARS-CoV genome. Another possible 
explanation for the difference in pathogenicity of HCoV-NL63 and SARS-CoV is a difference 
in interaction of S with ACEII or a different binding site on ACEII. Hoffman et al. have 
shown that HCoV-NL63 has a much lower binding affinity to ACEII compared to SARS-
CoV. The S-protein may therefore partially account for the difference in pathogenicity of 
HCoV-NL63 and SARS-CoV (Hofmann, Pyrc et al. 2005). 
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5. The Coronavirus Nucleocapsid Protein 
The coronavirus nucleocapsid (N) protein is one of the most abundantly produced viral 
proteins within an infected cell (Krokhin, Li et al. 2003) and has several functions. The 
primary function is the formation of the ribonucleocapsid core, which requires homotypic N 
dimerization to form higher order oligomers (He, Dobie et al. 2004; Surjit, Liu et al. 2004; 
Luo, Ye et al. 2005; Yu, Gustafson et al. 2005; Chang, Sue et al. 2006; Luo, Chen et al. 2006) 
with subsequent interaction with viral RNA (Stohlman, Baric et al. 1988; Cologna, Spagnolo 
et al. 2000; Nelson, Stohlman et al. 2000; Fan, Ooi et al. 2005; Spencer and Hiscox 2006; 
Tan, Fang et al. 2006; Chen, Chang et al. 2007; Chang, Hsu et al. 2009; Huang, Hsu et al. 
2009; Ma, Tong et al. 2010). Once this particle has assembled it interacts with the membrane 
glycoprotein, which in turn interacts with the envelope protein (Lim and Liu 2001) during 
viral assembly (He, Leeson et al. 2004; Hurst, Koetzner et al. 2009). The N-protein has also 
been shown to interact with cellular heterogenous nuclear ribonuclear protein A1 (hnRNP-
A1), which is thought to play a role in RNA synthesis (Wang and Zhang 1999; Luo, Chen et 
al. 2005; Chang, Sue et al. 2006) and with the human cyclophilin A protein (Luo, Luo et al. 
2004). Besides the structural functions of the N-protein, it is also involved in the regulation of 
transcription, translation and replication (Baric, Nelson et al. 1988; Almazan, Galan et al. 
2004; Pyrc, Jebbink et al. 2004; Verheije, Hagemeijer et al. 2010) of viral RNA as it has been 
shown to interact with replication-transcription complexes (Verheije, Hagemeijer et al. 2010). 
It has also been shown to be involved in perturbation of host cell physiological processes (He, 
Leeson et al. 2003; Surjit, Liu et al. 2004; Surjit, Liu et al. 2006; Yan, Hao et al. 2006; 
Kopecky-Bromberg, Martinez-Sobrido et al. 2007). N is also highly immunogenic and has 
therefore served as a target for the development of diagnostic and sero-prevalence assays 
(Che, Qiu et al. 2004; Lau, Woo et al. 2004; Lehmann, Wolf et al. 2008; Das, Kammila et 
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al.2010) and for the possible production of various vaccines (Kim, Lee et al. 2004; Girard, 
Cherian et al. 2005). This high level of immunogenicity will be discussed in more detail in 
subsequent chapters. Posttranslational modifications of the N-protein include sumoylation (Li, 
Xiao et al. 2005), acetylation (Krokhin, Li et al. 2003) and phosphorylation (Calvo, Escors et 
al. 2005; Chen, Gill et al. 2005; Surjit, Kumar et al. 2005; White, Yi et al. 2007). 
 
5.1 Multimerization of Coronavirus N 
The primary function of the N-protein is to associate with the viral RNA to form a protective 
covering. To do this the N-protein must be able to recognize the viral RNA and it must be able 
to undergo N-N homotypic interactions and self-associate into an oligomer to form the 
nucleocapsid core (He, Dobie et al. 2004; Surjit and Lal 2008). A serine-argine (SR) rich 
region is essential for this multimerization and self-interaction of the N-protein in SARS-CoV, 
as deletion of these amino acids completely abolish N multimerization (He, Dobie et al. 2004). 
He and colleagues also reported that a serine deletion mutant not only affected 
multimerization of the N-protein, but also altered the cellular distribution of the protein (He, 
Dobie et al. 2004). Another study also identified a 209 amino acid region at the C-terminal 
domain of the SARS-CoV N-protein that contains the interaction site important for trimer, 
tetramer or hexamer formation (Surjit, Liu et al. 2004; Surjit and Lal 2008). These results 
however contradict the results of He et al.(2004) as the SR rich region lies outside the 209 
amino acid region proposed by Surjit et al.(2004). The dimerization process of the N-protein is 
therefore rather complicated and will be covered in more detail, along with RNA-N 
interactions, in subsequent chapters. 
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The major heterotypic protein interactions involved in assembly of coronaviruses is 
that between the N- and M-protein. The M-protein is the most abundantly expressed envelope 
protein and has a triple spanning transmembrane region with a large carboxy terminal in the 
interior of the virion which is responsible for interaction with the N-protein. The M-protein 
inserts into the membranes of the ER-GIC complex and combines with the N-protein during 
cellular budding (Hurst, Koetzner et al. 2009). A region of the N-protein (a.a. 168-208), which 
is also responsible for N-protein dimerization, is responsible for the interaction with M in 
SARS-CoV (He, Leeson et al. 2004). Since coronaviruses differ from other enveloped viruses 
(in that they lack the matrix protein that commonly links the envelope of the virus to the 
ribonucleocapsid core), interaction between the N- and M-proteins are essential for 
coronaviral assembly and maturation (He, Leeson et al. 2004). 
 
5.2 Intracellular Localization of the Nucleocapsid Protein 
Even though several studies have shown that the N-protein of several members of Nidovirales 
localize to the nucleus and/or nucleolus (Hiscox, Wurm et al. 2001; Wurm, Chen et al. 2001; 
Timani, Liao et al. 2005; Reed, Dove et al. 2006), others have shown that N localizes 
predominantly or exclusively to the cytoplasm (Rowland, Chauhan et al. 2005; Surjit, Kumar 
et al. 2005; You, Dove et al. 2005). This indicates that the localization of N to the nucleus or 
nucleolus is not a conserved property of nidoviruses (Rowland, Chauhan et al. 2005). There is 
currently no data concerning the localization of the N-protein of HCoV-NL63. 
Movement of N from the cytoplasm through the nuclear pore complex and into the 
nucleoplasm is dependent and initiated by a nuclear localization signals (NLSs) on the N-
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protein, which binds to a NLS-binding site on importin-α (Rowland, Chauhan et al. 2005). 
NLSs are enriched with basic amino acids (such as lysines and arginines) and generally 
conform to one of three types, i.e. monopartite (pat4 and pat7) and bipartite motifs (Rowland, 
Chauhan et al. 2005). On the other hand, export of proteins from the nucleus is mediated by 
nuclear export signals (NESs); which are predominantly CRM-1-dependant signals (You, 
Dove et al. 2005). Nuclear pore complexes also allow for the passive transport of ions, small 
molecules and proteins with mass of 40 to 60 kDa in both directions between the cytoplasm 
and nucleoplasm. Coronavirus N-proteins from all three groups meet both criteria in that they 
have NLSs and are less than 50kDa in size (Wurm, Chen et al. 2001). 
 
5.3 Phosphorylation of the N-Protein 
Phosphorylation is a common post-translational modification and plays a role in the 
physiological functioning of proteins. N is heavily phosphorylated at multiple residues with 
the majority of phosphorylations occurring at serine residues. Surjit et al. (2005) showed that 
the N-protein of SARS-CoV is phosphorylated in the nucleus and cytoplasm. The stable 
phospho-protein then localizes to the cytoplasm and associates with the M-protein. In addition 
to the multiple phosphorylation sites on the N-protein for glycogen synthase kinase (GSK), 
protein kinase A and casein kinase (CK) I and II, there are also single sites for cyclin-
dependent kinases (CDK), protein kinase B, mitogen-activated protein kinase (MAPK) and 
polo-like kinase, indicating that the N-protein is phosphorylated at multiple sites by multiple 
enzymes. The coronavirus N-protein is phosphorylated immediately after synthesis and 
remains stably phosphorylated (Surjit, Kumar et al. 2005; Surjit and Lal 2008; Wu, Yeh et 
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al.2009). Cytosolic enzymes are responsible for phosphorylating the N-protein. It is, however, 
also possible that multiple kinases phosphorylate the N-protein in the cytoplasm and nucleus 
(Surjit, Kumar et al. 2005). N-proteins of many other coronaviruses are similarly 
phosphorylated, but the mechanism by which this occurs and the functional relevance thereof, 
if any, remains to be determined. Possible reasons for the phosphorylation of the N-protein 
may include: 1) increasing protein stability, 2) aiding in self-association of the protein into 
multimers for interactions with RNA, 3) playing a role in localization of the protein, 4) 
playing a role in nucleocytoplasmic shuttling (Chang, Sue et al. 2006)or 5) creating a more 
favorable environment for viral replication by modulating activity of kinases (Surjit, Kumar et 
al. 2005). Chen et al. (2005) have identified phosphorylation sites that are proximal to RNA 
binding domains. They noted that phosphorylated N-proteins bind to viral RNA with the same 
affinity as non-phosphorylated N-proteins. Importantly though, the phosphorylated N-proteins 
bind with a higher affinity to viral RNA than to non-viral RNA. This may indicate that 
phosphorylation of the N-protein may increase its ability to recognize viral RNA (Chen, Gill 
et al. 2005). 
 
5.4 Perturbation of Host Cell Processes by the N-protein 
The N-protein of coronaviruses has been known to act as a regulatory protein and thereby 
perturb certain cellular processes. To date, coronavirus N proteins have been shown to cause 
deregulation of the host cell-cycle (Wurm, Chen et al. 2001; Surjit, Liu et al. 2006), inhibit the 
production of interferon (Kopecky-Bromberg, Martinez-Sobrido et al. 2007), up-regulate the 
production of COX2 (Yan, Hao et al. 2006), up-regulate AP1 activity (He, Leeson et al.2003), 
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induce apoptosis in serum starved COS1-cells (Surjit, Liu et al. 2004) and interact with 
various cellular proteins including cyclophilin A (Luo, Luo et al. 2004) and hnRNP-A1 (Wang 
and Zhang 1999; Luo, Chen et al. 2005), which may have possible pathological consequences. 
 
5.4.1 Deregulation of host cell-cycle 
Deregulation of the host cell cycle is a common strategy employed by certain viruses which 
enable them to exploit the host cell machinery for their own benefit. Different steps in the host 
cell cycle typically include the G1 phase (preparation for DNA synthesis), S phase (replication 
of the genome), G2 phase (preparation for cell division) and the M phase (mitosis). 
Expression of the N-protein of TGEV and MHV leads to the inhibition of host cell 
proliferation induced by a cell cycle delay or arrest, most likely in the G2/M phase (Wurm, 
Chen et al. 2001). On the other hand, the N-protein of SARS-CoV inhibits the S-phase in 
mammalian cell lines by inhibiting the activity of the cyclin-CDK complex, which results in 
hypophosphorylation of retinoblastoma protein and subsequent down-regulation of the S phase 
gene products (Surjit, Liu et al. 2006). 
 
5.4.2 Inhibition of interferon production 
Interferon (IFN) production by the host cell is a key defense mechanism against infection. 
SARS-CoV infection, however, does not result in the production of interferon even though 
pretreatment of cells with interferon inhibits SARS-CoV infection (Surjit and Lal 2008). This 
indicates that SARS-CoV has developed a response to overcome the IFN defense. When cells 
are virally infected, several transcription factors are activated, including IRF-3 and NF-κB. 
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These transcription factors induce the expression of the IFN gene. Interferon is then 
synthesized and released from cells and binds to its receptors inducing the JAK/STAT 
signaling cascade pathway. This cascade pathway results in the activation of transcription 
factors which translocate to the nucleus and activate genes containing an interferon-stimulated 
response element (ISRE). Activation of the ISRE allows cells to combat viral infection and 
prevent viral replication (Kopecky-Bromberg, Martinez-Sobrido et al. 2007). 
In a previous study, Kopecky-Bromberg et al. (2006) showed that SARS-CoV ORF 
3b, ORF 6 and N antagonize the action of interferon. They showed that while N inhibits the 
production of IFN, ORF 3b and ORF 6 inhibit both IFN production and IFN signaling. 
Whereas IRF-3 was inhibited in cells expressing the N, ORF 3b and ORF 6, NF-κB was only 
inhibited in cells expressing N. ORF 3b and ORF 6 was also shown to block ISRE, with ORF 
6 shown to inhibit the translocation of STAT 1. These results show that SARS-CoV has at 
least 3 proteins which are able to inhibit certain aspects of the IFN response (Kopecky-
Bromberg, Martinez-Sobrido et al. 2007). 
 
5.4.3 Up-regulation of COX-2 
Cyclo oxygenase-2 (COX-2) protein is another pro-inflammatory molecule which, when 
stimulated in SARS-CoV infection, results in inflammation of the lungs. The SARS-CoV N-
protein stimulates the activation of COX-2 by binding to the COX-2 promoter. This activation 
of COX-2 requires binding to a NF-κB binding site and a CCAAT/enhancer binding protein 
binding site. SARS-CoV N-protein was able to bind directly to both of these regulatory 
sequences (Yan, Hao et al. 2006). 
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5.4.4 Up-regulation of the activator protein (AP) 1 pathway 
The AP-1 pathway is involved in cellular processes including cell proliferation, differentiation 
and apoptosis. The levels of transcription factors binding to promoter sequences of c-Fos, 
ATF2, CREB-1 and FosB was increased during the expression of SARS-CoV N-protein. Since 
the AP-1 signal transduction pathway is composed of homodimers and heterodimers of these 
molecules, He et al. (2003) proposed that the AP-1 signal transduction pathway is activated by 
the SARS-CoV N-protein. This was confirmed using the PathDetect system and the N-protein 
was shown to activate the AP-1 pathway in a dose dependent manner. The mechanism 
involved in the activation of this pathway, however, remains unknown (He, Leeson et al. 
2003). 
 
5.4.5 Induction of apoptosis in serum starved COS1-cells 
The SARS-CoV N-protein induces apoptosis in COS-1 cells in the absence of growth factors. 
The induction of apoptosis is induced by 1) downregulation of Erk, 2) upregulation of p38 
MAPK (MAPK/Erk pathway is involved in cell division), 3) upregulation of Jnk (c-Jun N-
terminal kinases: involved in apoptosis, cell differentiation and proliferation, inflammation 
and cytokine production), 4) downregulation of P-Akt and Bcl-2 (anti-apoptotic) and 5) 
induction of caspase 3 and 7 (pro-apoptotic). The activation of the p38 MAPK pathway 
induces actin reorganization in the absence of growth factors. Both the induction of apoptosis 
and actin reorganization induced by the activation of p38 MAPK are independent of each 
other as blocking the p38 MAPK pathway did not lead to inhibit activation of caspase 3, 
indicating 2 independent functional properties of N. The induction of apoptosis was also 
shown to be independent of the Fas, Fas ligand mediated pathway. This cell death was shown 
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to be tissue type specific as no significant cell death was observed in human hepatoma cells of 
epithelial cell lineage (Surjit, Liu et al. 2004). 
 
5.4.6 Binding of N-protein to cyclophilin A 
Cyclophilins have a high affinity against cyclosporine A, which is an immunosuppressive drug 
used to prevent allograph rejection. Cyclosporine A also blocks HIV-1 viral infection where 
cyclophilin A has recently been shown to have important implications in HIV infection by 
having an essential role in replication. Cyclophilin A interacts with the capsid domain of HIV-
1. Although the SARS-CoV genome does not encode a HIV-like capsid protein, sequence 
alignment shows homology between the SARS-CoV N-protein and HIV-1 capsid protein. This 
homology indicates that the N-protein of SARS may function in the same way as HIV-1 
capsid protein. Luo et al. (2004) verified interaction between the SARS-CoV N-protein and 
cyclophilin A using surface plasmon resonance and mutagenesis experiments. They showed 
that SARS-CoV N-protein binds to cyclophilin A with a much higher affinity than that of 
HIV-1 capsid protein (100-2700 times higher). This observation may provide some evidence 
of a possible pathogenicity factor of SARS-CoV (Luo, Luo et al. 2004). 
 
Aims of this thesis 
Human coronaviruses have recently been shown to cause both upper and lower respiratory 
tract infections which often leads to hospitalization. With the exception of SARS-CoV, the 
other four known human coronaviruses - HCoV-229E, HCoV-OC43, HCoV-NL63 and 
HCoV-HKU - continually circulate in the human population. HCoV-NL63 was identified in 
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2004 from the nasal aspirate of a child with respiratory symptoms. Although many reports of 
clinical data for this virus have since been reported, the virus is not well characterized at the 
molecular and protein levels. Therefore, this dissertation focuses on the in silico and in vitro 
characterization of the HCoV-NL63 structural nucleocapsid protein. 
 
Bioinformatic tools will be used to characterize the HCoV-NL63 N-protein, as well as 
identify selected motifs and/or regions important for protein functionality. Comparing HCoV-
NL63 N to other coronavirus homologues will shed light on the possible role(s) of this protein 
in determining HCoV-NL63 pathogenicity and infectivity.  
 
To identify antigenic epitopes on the N-protein, patient serum samples will be 
screened. For this reason HCoV-NL63 N-gene will be amplified and cloned for expression in 
a bacterial system. Purified recombinant HCoV-NL63 N-protein will be used to develop an 
ELISA that will be used to screen the patient samples.   
 
Not much is known about the proteins of HCoV-NL63, including the N-protein. The 
work that will be reported in this thesis, will serve as a prelude to extensive laboratory 
characterization of this protein. It will therefore form a crucial “first-step” in many other 
projects - which will fall outside the scope of this MSc project -, including in the generation of 
antibodies for the development of an antigen-capture ELISA that will be used to screen patient 
samples collected in the Western Cape.  
 
Major Outcomes will include 
 Bioinformatic characterization of the HCoV-NL63 N-protein. 
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 Cloning, expression and purification of the HCoV-NL63 N-protein and generation of 
truncated clones. 
 Characterizing the N-specific antibody cross-reactivity between coronavirus species and 
identify the antigenic epitope of the HCoV-NL63 N-protein. 
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 This chapter is an expanded version of the manuscript in preparation for submission 
as:  M. Berry, Y.J. Tan and B.C. Fielding, Analysis of the human coronavirus-NL63 
nucleocapsid protein, African Journal of Biotechnology. For this manuscript the 
Results and Discussion sections are combined. 
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1. Abstract 
The advent of genome sequencing technologies has resulted in large databases of genomes and 
the rate of genome sequencing has surpassed our ability to determine the function of the 
proteins they encode. In silico analysis has given us the ability to predict the function of these 
proteins, which can then be verified with the use of in vitro and in vivo studies. 
Bioinformatic tools were used for the comparative analysis of HCoV-NL63 N and 
selected coronaviruses N-homologues. Multiple sequence alignment tools were used to 
identify conserved regions and/or motifs within the coronavirus N-proteins. Next, the 
order/disorder state (which may indicate regions of interaction) of N was identified with 
PONDR. NetPhos 2.0 and DEPP were used to identify the putative phosphorylation state of 
the N-protein. Lastly, the peptide select tool of Invitrogen was used to characterize the 
antigenicity of the N-protein and identify putative antigenic epitopes. 
The HCoV-NL63 N-gene was predicted to encode a ~42.6 kDa protein most similar to 
HCoV-229E N (43% amino acid identity; 63% amino acid similarity). PONDR identified one 
disordered region in the HCoV-NL63 N-protein. N was shown to be highly phosphorylated by 
multiple kinases at multiple serine residues. HCoV-NL63 N was shown to be highly antigenic 
with a spike in antigenicity from residues ~140-180 for HCoV-NL63. This manuscript reports 
the computational analysis of the human coronavirus NL63 N-protein by comparing the amino 
acid sequences of coronavirus N-homologues.  
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2. Introduction 
The recent advent of genome sequencing technologies has provided large genome sequence 
databases and the rate at which genomes are sequenced has surpassed our ability to determine 
the function of the proteins these genomes encode. In silico analysis provides us with a tool to 
predict possible functions of these proteins by comparing novel proteins of unknown function 
with proteins of known function, or by analyzing the unknowns using an algorithm based on 
proteins of known function. These results can then be verified with the use of in vitro and in 
vivo studies. 
All N-proteins have the same primary function, to form the ribonucleoprotein core. 
However, using multiple protein sequence alignment with ClustalX the coronavirus N-
homologues were shown to have low sequence homology. Formation of this structure requires 
self-association of the N-protein into dimers and higher oligomeric structures, as well as 
interaction with viral RNA. This may indicate that the regions of interaction within the N-
protein share a higher sequence homology than that of the overall N-protein. 
SARS-CoV N is the most highly characterized of the coronavirus N-proteins, with the 
first evidence of dimerization shown using a mammalian two-hybrid system. A serine/arginine 
(SR) rich motif between residues 184 and 196 was shown to be essential for the dimerization 
of N (He, Dobie et al. 2004). Another study showed that dimerization of N occurs via a 209 
amino acid region of the C-terminal, which lay upstream of the SR rich motif (Surjit, Liu et al. 
2004). These results show that the process of N dimerization is complicated. In two later 
studies this C-terminal region was, however, reduced to residues 283-422 (Luo, Ye et al. 
2005; Yu, Gustafson et al. 2005). The SR rich motif was found to be responsible for 
dimerization by interacting with the middle region (a.a. 211-290) and dimerization of this 
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region inhibits the formation of multimers in the C-terminal (a.a. 283-422) domain (Luo, Ye et 
al. 2005). A C-terminal fragment between 343 and 402 (Luo, Chen et al. 2006) was later 
found to be sufficient for oligomerization of the N-protein. As this region has been supported 
by several researchers we have assumed it to be the probable region responsible for 
dimerization with the function of the SR rich motif yet to be properly elucidated. 
Other Coronavirus N-proteins are less well characterized with the dimerization 
domains of only MHV, IBV and OC43 being mapped.  The region of dimerization of the 
MHV N-protein was shown to occur via the N-terminal residues, 1-292, using a GST-binding 
assay (Wang and Zhang 1999). The IBV N-protein was found to dimerize at the C-terminal, 
spanning residues 218-329 (Fan, Ooi et al. 2005). Finally, the dimerization region of OC43 
was identified to be between residues 301 and 448 of the C-terminal (Huang, Hsu et al. 2009). 
Another protein-protein interaction pivotal in viral particle assembly is that between 
the N- and M-protein. The interaction links the ribonucleocapsid core to the envelope of the 
virus as the M-protein is the most highly expressed envelope protein (Kuo and Masters 2002). 
This region has only been characterized for SARS-CoV, where it was identified by a 
mammalian two-hybrid system and located between residues 168-208 (He, Leeson et al. 
2004), and for MHV which was characterized as a negatively charged domain in the C-
terminal, spanning residues 406-454 (Verma, Bednar et al. 2006). 
The N-protein has been shown to interact with the leader RNA sequence (Baric, 
Nelson et al. 1988), the 3′-end of the genomic RNA (Nelson, Stohlman et al. 2000; Zhou and 
Collisson 2000), the transcriptional regulatory sequence (Grossoehme, Li et al. 2009) and the 
packaging signal (Chen, Gill et al. 2005). Interactions between the CoV RNA and N 
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predominantly occur via the N-terminal domain. However, several binding sites, spanning 
both the N- and C-terminal domains of N as well as the 3 disordered regions linking these 
domains, are involved in RNA binding(Chang, Hsu et al. 2009). For SARS-CoV N these 
binding sites were mapped to the N-terminal amino acid (a.a.) residues 45-181 (Huang, Yu et 
al. 2004; Chang, Sue et al. 2006; Chen, Chang et al. 2007) and to the C-terminal residues 248-
365 (Chen, Chang et al. 2007), which has a stronger nucleic acid binding affinity than the N-
terminal. The RNA binding domain of MHV N was mapped to residues 177-231 (Nelson, 
Stohlman et al. 2000). HCoV-OC43 N has 3 possible RNA binding domains, spanning the N-
terminus (a.a. 1-173) and middle region (a.a. 174-232 and a.a. 233-300), with the N-terminal 
portion having the highest affinity for RNA (Huang, Hsu et al. 2009). Finally, the RNA 
binding domain of IBV N was mapped between residues 91-171 of the N-terminal and 
residues 203-409 of the C-terminal, where binding affinity was greater at the C-terminal 
domain (Zhou and Collisson 2000). As the N-terminal of CoV N-proteins is more highly 
conserved (Sastre, Dijkman et al. 2011) we have aligned these regions to identify sequence 
homology. 
Multiple sequence alignment of these experimentally proven regions within the N-
protein of the previously mentioned coronaviruses showed very low sequence homologies 
with few conserved regions. These results possibly indicate that other properties play a bigger 
role in interactions of the N-protein. For this reason we have chosen to identify the 
order/disorder state of the coronavirus N-proteins. 
A disordered protein, or region of a protein, refers to the lack of a tertiary structure and 
these proteins have no fixed 3 dimentional shape. A disordered protein has various functions 
including DNA, RNA and protein binding as the disordered region allows access to these 
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binding sites. On binding, the protein is understood to go through a disorder-to-order transition 
(Dunker, Garner et al. 1998; Garner, Romero et al. 1999; Dunker, Lawson et al. 2001). 
Interestingly, the amino composition, sequence complexity, hydrophobicity and charge etc. 
adjacent to phosphorylation sites is similar in disordered regions and therefore indicates that 
disorder is important for phosphorylation. We can therefore assume that the majority of 
predicted phosphorylation sites occur within the disordered regions of the N-protein 
(Iakoucheva, Radivojac et al. 2004). 
Given that the order/disorder state of a protein may play a large role in homologous 
and heterologous protein interactions, it would also be interesting to identify the antigenic 
state of the protein and attempt to identify whether there is an increase in antigenicity over 
these disordered regions. Two methods, namely the Welling (1985) and Parker (1994) 
methods, were used to identify the antigenic state of the SARS-CoV and HCoV-NL63 N-
protein (Welling, Weijer et al. 1985; Parker, Bednarek et al. 1994).  
We have used various bioinformatic tools to compare the N-proteins of the novel 
coronavirus, HCoV-NL63 (Amsterdam1 strain) and other coronaviruses. The HCoV-NL63 N 
protein sequence was shown most similar to HCoV-229E N (43% amino acid identity; 63% 
amino acid similarity). PONDR identified one disordered region in HCoV-NL63 N. N was 
shown to be highly phosphorylated by multiple kinases at multiple serine residues. HCoV-
NL63 N was predicted to be highly antigenic with a spike in antigenicity from residues ~140-
180 for HCoV-NL63. 
 
 
 
 
 
 
Chapter 2 
39 
 
3. Materials and Methods 
3.1 Multiple Sequence Alignment 
Nucleotide sequences were obtained from NCBI (accession numbers in brackets): HCoV-
NL63 (DQ846901.1), SARS-CoV (AY360146.1), MHV (AAU06361), IBV (AAA46214), 
HCoV-OC43 (AY585229.1), HCoV-229E (AAG48597), TGEV (AAA47915), PEDV 
(AF353511), HKU1 (AAT98585) and HKU7 (DQ666343). Selected N-homologues were 
aligned with CLUSTAL X version 2.0 (Larkin, Blackshields et al. 2007) and viewed with 
GeneDoc version 2.6.002 software (Nicholas and Nicholas 1997). 
 
3.2 Order-Disorder Prediction 
PONDR (Predictors of Natural Disordered Regions) was used to predict possible disordered 
regions within the SARS-CoV and HCoV-NL63 N-protein. PONDR (http://www.pondr.com) 
uses several algorithms, including VL-XT, XL1-XT, VL3 and VSL1 to predict possible 
disordered regions. We have chosen to use the VL-XT and VSL1 algorithms. The VL-XT 
incorporates 3 feedforward neural networks which are based on long disordered regions 
characterized by x-ray chrystallographic data (Romero, Obradovic et al. 1997; Li, Romero et 
al. 1999; Romero, Obradovic et al. 2001). The VSL1 utilizes two algorithms for short (<30aa) 
and long (>30aa) disordered regions and is trained on 1335 protein sequences (Obradovic, 
Peng et al. 2005). 
 
3.3 Phosphorylation State Prediction 
NetPhos 2.0 and the DEPP (Disorder Enhanced Phosphorylation Predictor) programs of 
PONDR were used to predict possible phosphorylation sites in the N-protein of HCoV-NL63 
and SARS-CoV (Blom, Gammeltoft et al. 1999). NetPhos 2.0 predicted serine, threonine and 
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tyrosine phosphorylation sites when threshold values (ranging from 0.0000 to 1.0000) were 
above 0.5. However values closer to 0.5 are less likely to be functional phosphorylation sites 
compared to motifs closer to 1.0. DEPP is based on 1500 experimentally confirmed 
phosphorylation sites. 3Dinsight motif finder was used to predict possible kinases responsible 
for the phosphorylation of these residues by identifying specific patterns in the amino acid 
sequence.  
 
3.4 Characterization of Antigenic State 
The peptide select tool of Invitrogen, which utilizes methods described by Welling (1985) and 
Parker (1994), was used to characterize the antigenic state of the SARS-CoV and HCoV-NL63 
N-protein. The Welling method describes how an immunogenic peptide has an approximate 
length of 6-7 amino acids, and based on previously identified antigenic epitopes from 20 
proteins, an average composition of an antigenic region can be identified. The Welling method 
therefore scans each 7 amino acids to identify the antigenicity of that region (Welling, Weijer 
et al. 1985). The Parker method utilizes a similar approach, however, it also incorporates 
amino acid side chains (Parker, Bednarek et al. 1994). 
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4. Result and Discussion 
4.1 Multiple Sequence Alignment 
The N-protein of HCoV-NL63 was compared to several other coronavirus nucleocapsid 
homologues using multiple sequence alignment with ClustalX to determine degree of 
sequence homology, as well as the presence of any possible conserved regions within the 
selected coronavirus N sequences. The amino acid sequence of HCoV-NL63 N was compared 
to other coronavirus N proteins (Table 2.1). HCoV-NL63 was shown to be most similar to the 
human coronavirus HCoV-229E N (43% identity; 63% similarity). This was not totally 
unexpected, since previous molecular clock analyses estimate that HCoV-NL63 and HCoV-
229E evolved from a most recent common ancestor in the 11
th
 century (Pyrc, Dijkman et al. 
2006). Interestingly, HCoV-NL63 N also showed high amino acid similarity to the bat 
coronavirus HKU7 N (40% identity; 57% similarity). As speculated previously (Fielding and 
Suliman 2009), this high amino acid similarity raises interesting questions about the 
relationship between this human and bat coronavirus: Could a bat be the original host of 
HCoV-NL63? In fact, present evidence shows that bat coronaviruses are the gene pools of the 
Group 1 and Group 2 coronaviruses (Woo, Lau et al. 2009). 
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Table 2.1: Multiple sequence alignment of 10 coronavirus nucleocapsid homologues. Sequence identity (top 
value) and similarity (bottom value) is shown. 
       NL63   SARS    MHV    IBV   OC43   229E   TGEV   PEDV   HKU1   HKU7 
 
NL63    377    20%    17%    15%    16%    43%    31%    36%    18%    40% 
               33%    30%    30%    31%    63%    51%    50%    33%    57% 
 
SARS           422    28%    20%    26%    19%    22%    17%    27%    20% 
                      42%    33%    42%    33%    38%    30%    42%    33% 
 
MHV                   454    17%    70%    18%    18%    15%    65%    17% 
                             31%    81%    33%    35%    30%    80%    31% 
 
IBV                          409    16%    13%    16%    14%    17%    15% 
                                    30%    25%    30%    27%    30%    28% 
 
OC43                                448    18%    18%    14%    62%    14% 
                                           32%    33%    30%    76%    31% 
 
229E                                       389    32%    31%    19%    38% 
                                                  49%    48%    33%    55% 
 
TGEV                                              382    25%    19%    31% 
                                                         43%    36%    48% 
 
PEDV                                                     441    14%    37% 
                                                                29%    52% 
 
HKU1                                                            441    17% 
                                                                       34% 
 
HKU7                                                                   391  
 
 
 
Comparative analysis of 10 coronavirus species identified a 9 amino acid region 
conserved between the N homologues, i.e. FYY(L/S)(G/A)TGPH (amino acid 78-86 for 
HCoV-NL63, Figure 2.1). Conserved regions within a family of proteins are commonly 
indicative of structural and functional conservation, as well as an evolutionary relationship. 
The function of this sequence, if any, is yet to be elucidated. However, this conserved amino 
acid region was shown to be present in previously identified RNA binding domains of other 
coronavirus N-proteins (Figure 2.2), indicating a possible role in RNA binding. Site-directed 
mutagenesis of residues in this region may be necessary to elucidate any definitive role it 
plays in RNA binding. 
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Figure 2.1: Alignment of the amino acid sequences of HCoV-NL63 N and selected coronavirus N-
homologues. Shading indicates conserved regions (black: 100% homology; dark grey: 80% homology: light 
grey: 60% homology) and gaps were introduced to align sequences. The conserved motif is boxed. 
 
 
Figure 2.2: A Conserved region (blocked) within the N-terminal of the nucleocapsid protein of 4 
coronaviruses. Regions aligned have been identified from literature and are shown to be responsible for RNA 
binding (references can be found in Table 2.2). Shading indicates conserved regions (black: 100% homology; 
dark grey: 80% homology: light grey: 60% homology) and gaps were introduced to align sequences. 
 
The N-protein of Group II coronaviruses show a higher sequence homology compared 
to that of Group I coronaviruses, with several more conserved regions found within the viruses 
of Group II. The 4 coronaviruses analyzed from Group II (SARS-CoV, HCoV-OC43 , MHV 
and HKU1) contained the  conserved motif of PRQKR (amino acid: 259-264 for SARS-CoV: 
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Figure 2.3), which was predicted by PSORTII to structurally form a nuclear localization signal 
(NLS). This indicates that conserved regions within a protein likely form a functional unit. 
This conserved region is absent in Group I viruses. 
 
Figure 2.3: Multiple sequence alignment of 4 Group II N-homologues. Shading indicates conserved regions 
(black: 100% homology; dark grey: 80% homology: light grey: 60% homology) and gaps were introduced to 
align sequences. The conserved motif (boxed) was predicted to structurally form an NLS. 
 
Multiple sequence alignment has shown an overall low sequence homology between 
the N homologues, however all N-proteins have the same primary function i.e. the formation 
of the ribonucleocapsid core. This process involves N-N homotypic interactions and RNA-N 
interactions. These have been experimentally plotted by various researchers and the domains 
have been summarized in Table 2.2, which also summarizes the region of N-M interaction for 
SARS and MHV N. M-N heterotypic interactions have been shown to be important in viral 
assembly. We have used multiple sequence alignment to determine whether these 
experimentally determined regions have a higher sequence homology compared to that of the 
overall homology. 
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Table 2.2: Regions of interaction within the coronavirus nucleocapsid proteins. 
 Region of 
Multimerization 
M-N Interaction Region of RNA 
Interaction 
SARS-CoV 343-402 
(Luo, Chen et al. 2006) 
168-208 
(He, Leeson et al. 2004) 
45-181 
(Huang, Yu et al. 2004) 
MHV 1-292 
(Wang and Zhang 1999) 
406-454 
(Verma, Bednar et al. 2006) 
177-231 
(Nelson, Stohlman et al. 2000) 
IBV 218-329 
(Fan, Ooi et al. 2005) 
 91-171 
(Zhou and Collisson 2000) 
HCoV-OC43  301-448 
(Huang, Hsu et al. 2009) 
 1-173 
(Huang, Hsu et al. 2009) 
 
4.1.1 Nucleocapsid Dimerization 
Multiple sequence alignment of the fragments responsible for N-N interactions showed very 
low sequence homology with the highest being between SARS-CoV and HCoV-OC43 (10% 
identity and 23% similarity). These results show even lower homology than compared to that 
of the full length N homologues; no conserved regions were identifiable between the 4 
fragments. This indicated that there is probably no consensus sequence for N-protein 
dimerization. However, the SR rich motif (responsible for dimerization) was relatively well 
conserved between the 10 coronavirus species aligned (Figure 2.4). There is a lot of 
contradictory information regarding the dimerization process of the N-protein - especially with 
regards to SARS-CoV N - and therefore the role of this SR-rich motif may be under-presented. 
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Figure 2.4: Conserved SR rich domain (blocked) within coronavirus nucleocapsid proteins. Shading 
indicates conserved regions (dark grey: 80% homology: light grey: 60% homology) and gaps were introduced to 
align sequences. 
 
4.1.2 N-M Heterotypic Interactions 
Multiple sequence alignment of the regions shown to be responsible for N-M interactions also 
showed very low sequence homology, indicating no known conserved region for N-M 
interactions. 
 
These results indicated that sequence homologies play little or no role in homologous 
or heterologous protein-protein interactions as few conserved regions were identifiable within 
these experimentally determined regions. It may also indicate that structural properties, such 
as order/disordered state, electrostatic forces and disulphide bond formation, within the protein 
may be more significant in protein-protein interactions compared to sequence homology. 
 
4.2 Order/Disorder 
Using the VL-XT and VSL1 algorithms the SARS-CoV N-protein has been shown to have 3 
possible disordered regions located at the N-terminus (residue 1-69), middle (residue 152-292) 
and C-terminus (residue 358-422) (Figure 2.5).  
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Figure 2.5: Predicted disordered regions of the SARS N-protein using PONDR algorithms. Regions above a 
threshold of 0.5 indicate residues which may be involved in a disordered region. Solid black lines indicate a 
predicted disordered region identified by the VSL1 (purple) and VLXT (red) algorithm. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Predicted disordered regions of the HCoV-NL63 N-protein using PONDR algorithm. Regions 
above a threshold of 0.5 indicate residues which may be involved in a disordered region. Solid black lines 
indicate a predicted disordered region identified by the VSL1 (purple) and VLXT (red) algorithm. 
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HCoV-NL63 N has only one putative disordered region spanning residues 109-248 
(Figure 2.6). Chang et al. (2005) used NMR to verify these claims and found that fragments 1-
44, 182-247 and 366-422 of SARS-CoV N are, infact, disordered. They also showed that 
several other coronavirus N homologues share the same pattern as that of SARS-CoV N 
(Chang, Sue et al. 2006), raising questions as to why HCoV-NL63 is different. 
SARS-CoV N interacts with the M-glycoprotein through residues 168-208 (He, Leeson 
et al. 2004). In this study, we used PONDR to show that this region falls within the middle 
disordered region of the SARS-CoV N indicating a possible necessity for state-of-disorder in 
interactions. In fact, the previously identified regions responsible for dimerization are located 
in disordered regions within the SARS-CoV N. (Surjit, Liu et al. 2004). Similarly, the SR-rich 
13 residue segment identified by He and colleagues (He, Dobie et al. 2004) and the RNA 
binding domain of SARS-CoV N (Huang, Yu et al. 2004), falls within disordered regions. If 
disorder is essential for RNA binding, the spanning of 2 disordered regions may explain the 
helical formation of the ribonucleoprotein. 
The presence of 3 disordered regions in SARS-CoV N compared to the 1 disordered 
region in HCoV-NL63 N may indicate that SARS-CoV N has a higher binding affinity to 
viral, as well as host cellular proteins. For example SARS-CoV N has been shown to tightly 
bind human cyclophilin-A through residues 235-369 (Luo, Luo et al. 2004), of which 
approximately 60 residues fall within a disordered region. The binding of cyclophilin-A to the 
N-protein has a great impact on pathogenicity of the SARS-CoV virus. This may indicate a 
probable basis for the increased pathogenicity of SARS-CoV compared to HCoV-NL63. 
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These results possibly indicate that the order-disorder structure of the N-protein plays a 
bigger role in protein interaction than that of sequence homology. If disorder is essential for 
these interactions, these results indicate that these interactions should take place between 
amino acids 109-248 of the HCoV-NL63 N-protein. Further experimental analysis, however, 
is needed to confirm these results. 
 
4.3 Prediction of Phosphorylation Sites 
For the HCoV-NL63 N a total of 34 possible phosphorylation sites were identified with 
NetPhos 2.0 including 29 serine, 3 threonine and 2 tyrosine residues; DEPP predicted 42 
possible phosphorylation sites with 32 serines, 6 threonines and 4 tyrosines. These results 
indicate that HCoV-NL63 N-protein is heavily serine phosphorylated at multiple residues 
(Figure 2.7). 3Dinsight motif finder identified multiple residues for phosphorylation by protein 
kinase C and casein kinase II. Protein kinase C exhibits a preference for the phosphorylation 
of serine or threonine residues found near to a C-terminal basic residue (Kishimoto, 
Nishiyama et al. 1985; Woodgett, Gould et al. 1986). Casein kinase II is another serine and 
threonine kinase, but has a preference for acidic residues (Pinna 1990). 
SARS-CoV N showed similar results with NetPhos 2.0 indicating a total of 33 possible 
phoshorylation sites of which 22 were serine, 8 threonine and 3 tyrosine. DEPP showed a total 
of 43 phosphorylation sites with 24 serine, 13 threonine and 6 tyrosines. This indicated that 
SARS-CoV N was also heavily serine phosphorylated at multiple residues (Figure 2.8). The 
SARS-CoV N also has predicted protein kinase C and casein kinase II phoshorylation sites, as 
well as 2 cAMP- and cGMP-dependant phosphorylation sites, which have been shown to 
 
 
 
 
Bioinformatic Analysis of the HCoV-NL63 N-Protein 
50 
 
phosphorylate serine and threonine residues in close proximity to at least two consecutive 
basic residues close to the N-terminal (Glass and Smith 1983; Glass, el-Maghrabi et al. 1986). 
 
 
Figure 2.7: Predicted phosphorylation sites of HCoV-NL63 N-protein. (a) Amino acid sequence showing 
position of serine, threonine and tyrosine residues. (B) Graph indicating phosphoryaltion-potential scores. 
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Figure 2.8: Predicted phosphorylation sites of SARS-CoV N-protein. (A) Amino acid sequence showing 
position of serine, threonine and tyrosine residues. (B) Graph indicating phosphoryaltion-potential scores. 
 
These NetPhos 2 results, which were substantiated by the DEPP predictions, indicate 
that both SARS-CoV and HCoV-NL63 N-proteins were heavily serine phosphorylated in the 
middle disordered regions. SARS-CoV N had a total of 14 serine residues (of a total 22 
residues; 64%) within its middle disordered region (residue 146-221) and HCoV-NL63 N had 
a total of 21 serine residues (of a total 29 residues; 72%) from residue 181-213. These results 
indicated that phosphorylation preferentially occurs within the disordered regions of the 
nucleocapsid protein. 
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4.4 Characterization of the antigenic state 
The methods described by Welling and Parker showed that both the SARS-CoV and HCoV-
NL63 N-protein were highly antigenic. The results indicated that the antigenic profiles of both 
N-proteins were similar with the Parker method showing a spike in antigenicity from residues 
~140-180 for HCoV-NL63 and residue ~175-220 for SARS-CoV (Figure 2.9). The method 
described by Welling could have missed this region of antigenicity as it does not incorporate 
amino acid side chains. Since both these regions fall within the disordered regions of these 
proteins, it could highlight another role of disorder in protein physiology. As both properties 
are independent of each other, it could also indicate an evolutionary relationship that the 
immune response has developed against amino acids which form the accessible disordered 
region and raises the question, “are immunogenic epitopes preferentially disordered?”. 
 
 
Figure 2.9: Antigenic profile of the SARS-CoV (bottom) and the HCoV-NL63 (top) nucleocapsid protein. 
A value above threshold (0) indicates an antigenic peptide. 
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5. Conclusion 
The HCoV-NL63 genome is approximately 27 553 nucleotides in size, with the typical 
coronavirus genome organization (Pyrc, Dijkman et al. 2006). It produces six separate 
mRNAs, with all potential ORFs encoding for viral proteins. N has been shown to be 
expressed from distinct subgenomic (sg) mRNA 6, the most abundant sg mRNA (Pyrc, 
Jebbink et al. 2004). Expression of recombinant HCoV-NL63 N in a bacterial system yielded 
a ~44 kDa protein (result not shown) which corresponded to the size of the putative 42.6 kDa 
predicted by our initial analysis (http://www.sciencegateway.org/tools/proteinmw.htm). 
Besides the relatively high conservation between the N-protein of NL63 and HCoV-
229E, other coronavirus homologues showed a significantly lower sequence homology. All 
coronavirus N-proteins, however, have the same primary function, i.e. the formation of the 
ribonucleocapsid core. This process requires self-association of the N-protein into dimers and 
higher oligomeric structures as well as interaction with viral RNA. Once this particle has 
assembled, the N-protein has been shown to interact with the M-protein during virion 
assembly. Is it then possible that these regions of interaction share a higher degree of 
homology compared to the full length N-protein?  
The conflicting literature on the dimerization status of the coronavirus N-protein raises 
a lot of questions as to the correct process involved in this interaction. Two possible regions 
have been identified to be responsible for the dimerization process; that being 1) the C-
terminal domain and 2) a SR-rich region. Multiple sequence alignment has shown that the C-
terminal region is weakly conserved between coronavirus N-homologues; however, the SR-
rich region has been shown to be relatively highly conserved. Do the conflicting results 
indicate that when truncated mutants of full-length N are cloned, several regions within the N-
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protein are capable of forming dimers, with only one region preferentially forming a dimer in 
vivo? SR rich domains have also previously been shown to mediate RNA binding, with the RS 
domains being required to mediate protein-protein interactions (Graveley and Maniatis 1998). 
Various SR rich proteins have been shown to have a major involvement in pre-mRNA 
splicing, however several researchers have also shown these domains to be responsible for 
mediating protein-protein interactions (Yuryev, Patturajan et al. 1996; Bourquin, Stagljar et al. 
1997; Yang, Embree et al. 1998). These results show that both the SR and RS domains can 
mediate protein-protein interactions and therefore may be responsible for mediating the 
dimerization of the N-proteins. 
With exception of the SR-motif, multiple sequence alignment reveals very little 
homology between regions shown to take part in dimerization and N-M heterotypic 
interactions. These regions do however fall within a disordered region, indicating that the 
protein’s order/disorder structure plays an important role in mediating these interactions as 
well as the phosphorylation state of a protein, as the majority of predicted phosphoryaltion 
sites occur within the middle disordered region. In silico analysis of proteins can therefore 
play an important function in determining which regions to construct as recombinant clones 
prior to the initiation of in vivo and in vitro studies. 
In silico analysis is a good indication of the structure of a protein, however, errors can 
occur and therefore claims must be substantiated with experimental evidence. The 
order/disorder state on the HCoV-NL63 N-protein has been reported to be different to that of 
other coronavirus N-proteins, with HCoV-NL63 N only having one disordered region 
compared to the 2-3 disordered regions within other coronavirus N-proteins (Chen, Gill et al. 
2005). As majority of protein-protein interactions occur within these disordered regions, it 
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indicates that residues 109-248 of the HCoV-NL63 N will form the hub of these interactions. 
This region is also understood to be highly phosphorylated and involved in eliciting an 
immune response as it contains highly antigenic peptides. This information will be used in the 
construction of recombinant clones to verify these claims in vitro. 
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1. Abstract 
Bacterial expression of proteins remains to be a popular method for the production of 
heterologous, recombinant proteins, which do not require post-translational modifications 
such as phosphorylation and glycosylation for activity. The nucleocapsid protein of HCoV-
NL63 and SARS-CoV has been cloned and expressed in a bacterial system for later use in an 
antibody capture ELISA for the detection of serum antibodies against HCoV-NL63. 
RT-PCR was used to generate cDNA using viral RNA as a template. The N and 
truncated N-genes of HCoV-NL63 were amplified from this cDNA, where the SARS-CoV N-
gene was amplified from a pXJHA40 vector. Amplified genes were then cloned into a pGEM
®
 
T-easy sequencing vector and used to transform JM109 E. coli. Once sequencing was 
confirmed, plasmids were isolated by alkaline lysis and the amplified gene was restricted 
using enzymes specific for ligation into a Flexi™ protein expression vector. This gene-vector 
construct was used to transform KRX E. coli which served as our protein expression model. 
Protein expression was confirmed by Western Blot analysis against the GST fusion protein, 
which was also used to facilitate purification. Once proteins were purified, the fusion protein 
was removed using ProTEV protease. 
The N-proteins of SARS-CoV and HCoV-NL63 were successfully expressed using the 
Flexi™/KRX expression system; however, a large degree of troubleshooting was necessary to 
optimize expression levels where several problems, including insolubility and background 
expression, were encountered. The system was also unable to adequately express the middle 
disordered region of the HCoV-NL63 N-protein. 
 
 
 
 
 
Cloning and Expression of the HCoV-NL63 N-Protein 
 
58 
 
2. Introduction 
The nucleocapsid (N) protein of coronaviruses is abundantly expressed during infection and is 
also highly immunogenic (Timani, Ye et al. 2004). For this reason it poses a good target for 
the development of a diagnostic assay. However, as a large majority of people have been 
exposed to HCoV-NL63 and other human coronaviruses (HCoV), with most HCoVs being 
able to cause re-infection throughout life (Sastre, Dijkman et al. 2011), the development of a 
diagnostic assay to screen for seroconversion would pose irrelevant as antibodies are almost 
always present. The N-protein has also been shown to be capable of cross-reaction with serum 
antibodies against other HCoVs (Sun and Meng 2004; Woo, Lau et al. 2004; Chan, Cheng et 
al. 2005; Che, Qiu et al. 2005; Vlasova, Zhang et al. 2007; Venter, Lassauniere et al. 
2011).Understanding how these antigens interact with serum antibodies against the virus is 
therefore of importance prior to the production of antibodies for the generation of an antigen 
capture enzyme linked immunosorbent assay (ELISA). 
Bacterial expression of proteins would allow for the production of the N-protein to 
characterize this interaction. Bacterial expression remains to be a popular method for the 
production of heterologous, recombinant proteins, which do not require post-translational 
modifications such as phosphorylation and glycosylation for activity. This method of protein 
production is used by both researchers and in the large scale manufacture of pharmaceuticals 
such as insulin (Masters 1992) due to the ability of bacterial cultures to rapidly reach a high 
optical density on relatively inexpensive substrates (François 1999). Bacterial expression is 
even capable of heteromultimeric expression of heterlologous proteins as seen with the 
expression of the α and β subunits of human hemoglobin to form a fully functional tetrameric 
structure (Hoffman, Looker et al. 1990). 
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This chapter will detail the cloning and bacterial expression of recombinant clones of 
the SARS-CoV and HCoV-NL63 N-genes corresponding to full-length SARS-CoV N and 
HCoV-NL63 N (N1), the N-terminal domain of HCoV-NL63 (N2), the C-terminal domain of 
HCoV-NL63 (N3) and the middle region of HCoV-NL63 (N4). The SARS-CoV N-gene is 
1269 base pairs (bp) and codes a putative 422 amino acid (aa) protein with a molecular weight 
of 46.05kDa. Full length SARS-CoV N will allow us to identify any antibody cross-reactivity 
between SARS-CoV and HCoV-NL63 antibodies. N1 is an 1134 bp sequence which codes a 
377 aa protein with a molecular weight of 42.6 kDa. N2 corresponds to the N-terminal half of 
N1 and spans residues 1-189 with a molecular weight of 21.51 kDa. N3 corresponds to the C-
terminal half of N1 and codes for residues 190-377 with a molecular weight of 20.9 kDa. 
Finally, N4 codes for the middle third region and overlaps both N2 and N3 and codes for aa’s 
127-252 with a molecular weight of 14.01 kDa (Table 3.1). 
Table 3.1: Description of heterologously expressed proteins. 
Gene Name 
Nucleotide  
Region 
Protein  
Region 
Molecular  
Weight (kDa) 
Fusion  
Tag 
SARS-N 1-1269 1-422 46.05 GST 
N1 1-1134 1-377 42.6 GST 
N2 1-567 1-189 21.51 GST 
N3 568-1134 190-377 20.9 GST 
N4 381-756 127-252 14.01 GST 
  
All clones were expressed downstream from a glutathione S transferase (GST) fusion 
protein, which is used to facilitate detection and purification as well as increase correct folding 
and solubility. Fusion proteins have been assumed to increase correct folding of their 
downstream partner as they reach a native conformation efficiently and rapidly, thereby 
promoting correct folding of the entire protein (François 1999). This fusion protein can be 
cleaved from the expressed protein using Tobacco Etch Virus (TEV) protease. 
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KRX (Promega) strain of competent E. coli was used for the expression of all 
constructs utilizing a Flexi™ (pFN2A) vector system. The Flexi™ vector utilizes two unique 
restriction enzymes, namely SgfI and PmeI, which ensures high fidelity, unidirectional cloning 
and also allows for easy transfer of the coding region between a variety of Flexi™ vectors. A 
lethal barnase gene is also located between the cloning sites, which upon successful ligation is 
replaced by the cloned gene. As the 5’ and 3’ ends cannot ligate together, this gene prevents 
the growth of cells which are not successfully ligated. KRX has a high transformation 
efficiency and is also nuclease and protease deficient, making it a good strain for cloning and 
protein expression (Hartnett, Gracyalny et al. 2006).The absence of these proteases and 
nucleases is crucial for efficient production of heterologous proteins as cytoplasmic 
degradation is employed by E. coli to conserve cellular resources (François 1999). KRX 
utilizes a T7 RNA polymerase gene, which is controlled by a rhamnose inducer, to provide 
tight control over protein expression via a T7 promoter, provided by the Flexi™ vector. The 
rhamnose is not metabolized during growth due to deletion of the isomerase, kinase and 
aldolase genes (Hartnett, Gracyalny et al. 2006).To inhibit the growth of plasmid free cells an 
antibiotic resistant gene is inserted into the plasmid, in our case an AmpR gene, which is used 
to incorporate ampicillin resistance. These antibiotics can however be degraded, inactivated or 
detoxified by leakage of periplasmic enzymes into the growth media (François 1999). 
Plasmids can be lost at a low frequency during cell division, however this loss can be 
increased if the ligated gene it carries is toxic to the cell (François 1999). It is therefore 
essential that selective pressures are installed to prevent the growth of plasmid free cells. The 
KRX and Flexi™ vector system has been proven to be a good model for the large scale 
expression of heterologous, recombinant proteins. 
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 In this study, expression of the SARS-CoV and HCoV-NL63 N recombinant proteins 
could be detected in both the soluble and insoluble fraction of the cell. This has not been 
reported in any other literature and is peculiar as the GST fusion tag is known to increase 
solubility of the expressed protein. Insolubility could arise through one of two mechanisms, 
that being; 1) the formation of inclusion bodies or 2) interaction with the cellular membranes 
of the host cell. Inclusion body formation occurs in cytoplasmically expressed proteins 
(Hannig and Makrides 1998) and are highly expressed, denatured, homologous proteins which 
aggregate together to form a high molecular weight structure (Singh and Panda 2005; Rinas, 
Hoffmann et al. 2007). Inclusion bodies are generally difficult to solubilize and refold, 
however, as these proteins are homologous it aids in isolation and purification. Inclusion body 
formation also generally protects proteins from degradation (François 1999). There are several 
methods to reduce the formation of inclusion bodies, but by far the simplest is reduction of the 
fermentation temperature. This reduction in temperature slows protein synthesis and decreases 
protein self-association (Georgiou and Valax 1996). Expression at low temperature and in the 
presence of ethanol has also been reported to decrease inclusion body formation as ethanol is a 
strong inducer of heat shock proteins which act as chaperones for the correct folding of 
expressed proteins (Steczko, Donoho et al. 1991).  
 Several attempts to decrease the formation of inclusion bodies were not shown to 
increase the proteins solubility, indicating that insolubility did not arise through formation of 
inclusion bodies. Lysozymes were subsequently used as they have the ability to digest the 
peptidoglycan layer of the bacterial cell wall (Peti and Page 2007). This digestion dramatically 
increased solubility and as this step was carried out following cell lysis it indicates that the N-
proteins interact with the peptidoglycan layer or another component of the bacterial cell wall. 
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By interacting these previously detailed, heterologously expressed proteins with serum 
antibodies against the protein we will be able to identify the antigenic epitope as well as any 
cross-reactivity between SARS-CoV and HCoV-NL63. These clones will also later be able to 
answer other questions regarding the dimerization process, regions involved in RNA binding, 
heterotypic protein interactions, etc. 
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3. Materials and Methods  
3.1 Amplification of Full Length and Deletion Mutant Nucleocapsid Genes 
3.1.1 RT-PCR 
HCoV-NL63 RNA (a kind gift from Prof. L van der Hoek, Holland) was used as template to 
synthesize 1st strand cDNA. RNA was extracted from a fifth-passage virus (strain Amsterdam 
1) obtained from a clinical sample. Reverse transcription was carried out using a mixture of 
2µl RNA template (108-109 copies/ml), 1µl of Oligo (dT)15 primer (100µM stock), 
1×incubation buffer, 2µl of dNTP mix (10mM stock), 20U RNasin
® 
Ribonuclease inhibitor, 
15U of AMV Reverse Transcriptase and 4µl MgCl2 (25 mM) and was made up to a total 
volume of 20µl in nuclease-free water, according to the manufacturer’s specifications 
(Promega). The reaction was heated at 42ºC for 60 min, 95ºC for 5 min and then cooled to 0ºC 
for 5 min to deactivate the enzyme. 
 
3.1.2 Design of PCR Primers 
For ligation into the Flexi™ protein expression vector it is necessary to artificially insert 
Flexi™ restriction sites into the gene of interest. To accomplish this, a SgfI (5´ GCGATCGC 
3´) restriction-site was incorporated into the forward primer and a PmeI (5´ GTTTAAAC 3´) 
restriction site was incorporated into the reverse primer. An additional C residue was 
appended upstream of the ATG in the forward sequence to prevent a frameshift in the reading 
frame. Primers were designed according to the NCBI accession number for SARS-CoV N, 
AY360146.1, and HCoV-NL63 N, DQ846901.1. Recombinant deletion mutants of N2 (NΔN), 
N3 (NΔC) and N4 (NΔNΔC) were also designed. For the N3 and N4 sequences an ATG was 
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incorporated to the 5’ as there was no existing start codon. The PmeI restriction site in the 
reverse primer will incorporate a stop codon in the 3’ if there is none present. An additional 4 
nucleotides were added to the 5’ and 3’ which promote a more complete digestion of the PCR 
product by SgfI and PmeI restriction enzymes. Genes of interest were amplified with primers 
described in Table 3.1. 
 
Table 3.2: Forward and reverse primer sequences constructed for PCR amplification of the SARS-
CoV N and HCoV-NL63 N-genes as well as truncated mutants of the HCoV-NL63 N-gene of N2, N3 
and N4. 
Gene Primer Primer Sequence 
SARS-CoV N Forward AGGAGCGATCGCCATGTCTGATAATGGACCCCAATCAAACC 
Reverse TTGTGTTTAAACTTATGCCTGAGTTGAATCAGCAGA 
HCoV-NL63 N1 
(Full length N) 
Forward GGGCGCGATCGCCATGGCTAGTGTAAATTGGGCCG 
Reverse ACAGGTTTAAACTTAATGCAAAACCTCGTTGACAATTTC 
HCoV-NL63 N2: 
N-terminal 
Forward GGGCGCGATCGCCATGGCTAGTGTAAATTGGGCCG 
Reverse TTGTGTTTAAACTTAAACAGCAGCAACAAGATCTGAA 
HCoV-NL63 
N3:C-terminal 
Forward TGTCGCGATCGCCATGACTTTGGCTTTAAAGAACTTAGGTTT
TGA 
Reverse ACAGGTTTAAACTTAATGCAAAACCTCGTTGACAATTTC 
HCoV-NL63 N4:  
Middle Region 
Forward TCTCGCGATCGCCATGTTCTCTATTGCTTTGCCTCCA 
Reverse GTCGGTTTAAACTTAAGGACCAAAGCACTGAATAACA 
SgfI cut site; PmeI cut site 
  
3.1.3 Polymerase Chain Reaction (PCR) and Purification of Amplified Genes 
The N-gene of HCoV-NL63 was amplified from cDNA of the virus, previously generated, 
where the N-gene of SARS-CoV was amplified from a pXJHA40 vector designed and 
provided by Prof. Tan (Singapore). The PCR reaction was set-up in a final volume of 25μl 
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with 0.2mMdNTP mix, 1.5mM MgCl2, 4μM forward and reverse primers (10pmole/ul), 5μl 
5x Green GoTaq Flexi™ buffer, 0.5μlGoTaq polymerase (5U/μl) and 2μlcDNA template. Of 
the 10 primers the lowest Tm was 64.68°C for the HCoV-NL63 N2 reverse primer and 
therefore an annealing temperature of 60°C was chosen to ensure high specificity of binding 
of base pairs to the template strand. PCR amplification was therefore run under the following 
conditions: 95°C for 3 min followed by 30 cycles of 95°C for 1 min, 60°C for 1min and 72°C 
for 2min. The final elongation was run for 15min at 72°C. 
The PCR product was diluted in a ratio of 1:6 with 6x Blue/Orange loading dye (0.4% 
(v/v) orange G, 0.03% (v/v) bromophenol blue, 0.03% (v/v) xylene cyanol FF, 15% (v/v) 
Ficoll
®
 400, 10mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0)) and run on a 1% (w/v) 
agarose gel, containing 0.001% (v/v) ethidium bromide, by electrophoresis in TBE (89mMtris 
(hydroxymethyl) aminomethane, 0.089mM boric acid, 2mM EDTA (pH 8)) buffer at 90V for 
approximately 1 hour. The agarose gel was viewed under short-wave length UV light and 
bands of interest were excised and dissolved in 1μl/mg membrane binding solution (4.5M 
guanidine isothiocyanate and 0.5M potassium acetate) at 60°C with frequent vortexing. The 
dissolved gel mixture was then transferred to a minicolumn assembly and incubated at room 
temperature for 1 min. The DNA was transferred to the minicolumn membrane by 
centrifugation at 14000rpm for 1 min. Electrostatic interactions generated in the presence of 
chaotropic salts allow DNA to bind to the silica membrane. The DNA was repeatedly washed 
with 700μl and 500μl membrane wash solution (10mM potassium acetate, 80% (v/v) ethanol 
and 16.7μM EDTA) by centrifugation at 14000rpm for 1 and 5 min respectively. A further 1 
min centrifugation at 14000rpm was necessary to ensure complete evaporation of residual 
ethanol in the washing solution. DNA was eluted in 30μl nuclease free water which 
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neutralizes the electrostatic interactions releasing the purified DNA from the membrane. The 
purified DNA was transferred to a clean 1.5ml eppendorf by centrifugation at 14000rpm. The 
purified PCR product was then quantified using a Qubit™ 1.0 fluorometer quantification 
system.  
 
3.2 Cloning and Verification of Amplification Products 
3.2.1 Ligation into pGEM
®
 T-easy Vector 
The PCR amplified viral gene was ligated into the pGEM
®
 T-easy sequencing and shuttling 
vector (Appendix 11) as per manufacturer’s instructions, which were set up as follows; 5μl 2X 
T4 DNA rapid ligation buffer, 1μl (50ng) pGEM® vector, 3μl PCR product and 1μl T4 DNA 
Ligase. The reaction was incubated at 4°C overnight to obtain the maximum number of 
transformants. The pGEM
®
 vector contains 3’ thymine overhangs in the cloning site which 
allows for easy ligation of the amplified product as the Taq polymerase incorporates a 
template-independent deoxyadenosine residue to the 3’ of the amplified fragment. pGEM® 
also allows for blue/white colony selection through the presence of a β-galactosidase gene, 
which, when disrupted by the successful ligation of the amplified fragment produces the 
formation of a white colony. On unsuccessful ligation the β-galactosidase gene remains active 
and in the presence of its inducer (IPTG) and substrate (Xgal) a blue colony is formed 
allowing for easy selection of successfully transformed cells. M13 primer recognition sites are 
also present up- and down-stream of the insert allowing for easy sequencing of the fragment. 
Several recognition sites for restriction enzymes are also present up- and down-stream from 
the cloning site allowing for a single-digestion to release the cloned gene.  
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3.2.2 Preparation of culture media 
Luria Bertani: LB media is the most common liquid media used in the cultivation of bacteria 
such as E. coli. It consists of 10g pancreatic digest of casein or tryptone powder, 5g yeast 
extract powder and 5g NaCl per 1L. A pH of 7.2 was established with the titration of 1M 
NaOH. Media was sterilized by autoclave, after which, 1μg/ml ampicillin was added, unless 
otherwise stated. 
LB agar: LB agar was prepared as per LB media with the addition of 15g agar bacteriologica. 
Agar was thoroughly dissolved by convection heat prior to autoclaving. For blue/white colony 
selection, seen with pGEM
®, 30μl 3% (v/v) Xgal and 100μl 0.1M IPTG was spread over the 
surface of the solidified agar. 
Terrific broth: Rich media such as terrific broth can be used to support cultures requiring a 
higher cell density. For protein expression cultures no significant difference was noted in final 
protein yield between LB and terrific broth, however, a higher cell density was beneficial for 
cultures used in plasmid extraction. Terrific broth was prepared with 12g tryptone powder, 
24g yeast extract powder, 4ml glycerol, 17mM KH2PO4 and 72mM K2HPO4which was 
thoroughly dissolved in 1L distilled water.  
 
3.2.3Transformation of JM109 E. coli and Screening for Recombinant Clones 
High transformation efficiency (>1x10
8 cfu/μg DNA) JM109 (Promega) competent E. coli 
cells were used for transformation. Transformations were followed as per manufacturer’s 
protocols with minor modifications. Briefly, 50μl competent cells were thawed on ice for 
approximately 5 minutes and 5μl ligation reaction was added to the cells, which were returned 
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to ice for approximately 20 min. The cells were then heat-shocked in a water bath at exactly 
42°C for 45 sec and returned to ice for 2 min. 950μl room temperature LB media, without 
ampicillin, was then added and incubated at 37°C for 1.5 hours. Cells were then pelleted at 
2000rpm for 10 min and resuspended in 200μl LB media. This cell suspension was spread-
plated on LB agar plates containing 1µg/ml ampicillin, 0.1M IPTG and 3% (v/v) Xgal and 
incubated at 37°C for 16-20 hours. 
 
Recombinant plasmids were screened by colony-PCR where white colonies were 
selected and inoculated into terrific media and a corresponding PCR mix. The cultures were 
incubated at 37°C for 14 hours. PCR reaction was run as previously described, where initial 
denaturation was increased to 5 min to ensure complete lysis of the cells and denaturation of 
template strand. Results were used to identify colonies with the correct gene construct and 
glycerol stocks were made of corresponding cultures. Glycerol stocks were prepared with 
750μl media and 250μl glycerol, which was thoroughly resuspended and stored at -80°C. The 
remaining culture was used for plasmid DNA extraction using the SV Mini-Prep kit 
(Promega).  
 
3.2.4 Plasmid Extraction 
The mini-prep (SV Mini-Prep, Promega) procedure is used to isolate plasmid DNA from 
bacterial cells using an alkaline lyses method. Manufacturer’s protocols advised using 2ml 
overnight culture for plasmid isolation however it was found that using a biomass (BM) index 
was more relevant to ensure the highest yield of plasmid DNA. Biomass was therefore 
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calculated using the following equation: OD600(mg/ml)xVol(ml)=BM(mg). A biomass of 
approximately 4mg was used for all mini-preps. After the cells were harvested by 
centrifugation at 14000rpm the pellet was resuspended in 250µl cell suspension buffer (50mM 
Tris-HCl, 10mM EDTA) containing 100ug/ml RNase. Cells were then lysed in an alkaline 
(pH 12) lysis buffer (1% (w/v) SDS, 0.2M NaOH) which denatures all DNA to its single 
stranded form. Plasmid DNA is, however, circular and therefore when the pH is neutralized 
(to pH 7), with the addition of 350µl neutralization buffer (80mM potassium acetate, 
8.3mMTris-HCl, 40μM EDTA), the plasmid can easily realign, where chromosomal DNA 
remains in a single stranded form and interacts with cellular debris. On centrifugation at 
14000rpm for 1min the cellular debris, with bound chromosomal DNA, is pelleted and 
therefore separated from plasmid DNA. The clear lysate is then transferred to a minicolumn 
and plasmid DNA is bound to the silica membrane with the same principle as in 3.1.3. 
Plasmid DNA is then washed with 700µl wash solution by centrifugation at 14000rpm for 
1min and eluted in 50µl nuclease free water and transferred, by centrifugation at 14000rpm, to 
a clean 1.5ml eppendorf. Plasmid DNA is stored at -20°C. 
 
3.2.5 Restriction Endonuclease Digestion 
As EcoRI restriction sites are located up- and down-stream from the cloning site, removal of 
the ligated product with these restriction enzymes was performed as a second confirmatory 
test. The restriction reaction was set up as follows; 2μl 10x buffer H (50mM Tris-HCl, 10mM 
MgCl2, 100mM NaCl), 0.2μl BSA (bovine serum albumin), 1.0μl EcoRI and 16.8μl isolated 
plasmid, which was incubated at 37°C for 3 hours in a water bath, following which, the 
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reaction was viewed on a 1% (w/v) agarose gel under UV light to confirm the presence of the 
viral gene. 
 
3.2.6 Nucleotide Sequencing and Sequence Analysis 
Extracted plasmids were sequenced with M13 forward and reverse primers to ensure no base-
pair mutations occurred. Sequencing reactions were conducted by Inqaba Biotechnical 
Industries (Ltd) Pty, South Africa. Results were viewed with FinchTV (www.geospiza.com) 
and extracted sequences were aligned using the multiple sequence alignment function in 
ClustalX (Version 2.0.12). Files were subsequently extracted to GeneDoc (Version 2.7.000) 
for viewing. 
 
3.3 Ligation into Flexi™ Vector and Transformation of KRX Competent E. coli 
3.3.1 Restriction with Flexi™ Enzymes (SgfI and PmeI) 
Flexi™ vectors (Appendix 12) contain a lethal, or barnase, gene between the SgfI and PmeI 
restriction sites, which prevents the growth of unsuccessfully ligated plasmids. This gene must 
first be removed with Flexi™ restriction enzymes before ligation with the viral gene. The 
barnase gene of the Flexi™ vector and viral gene ligated into the pGEM® vector was cut-out 
according to manufacturer’s instruction. Briefly, the restriction reaction to remove the insert 
from the pGEM
®
 vector was set up as follows, 4μl 5x Flexi™ digest buffer (10mM TrisHCl 
(pH 7.4), 150mM KCl, 50mM NaCl, 0.1mM EDTA, 1mM DTT, 0.25mg/ml BSA, 0.05% 
(w/v) Thesit
®
 and 50% (v/v) glycerol), 5μl (±0.1ug/ul) of the various recombinant plasmids, 
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1μl Flexi™ enzyme blend (SgfI and PmeI) and 10μl nuclease free water was incubated at 
37°C for 3 hours. The enzyme was then deactivated at 65°C for 20min. It was later noticed 
that yield was greatly increased when the nuclease free water was replaced with recombinant 
pGEM
®
 vector and therefore this volume was increased to 15μl and nuclease free water was 
removed from the reaction. The restriction reaction was run on a 1% (w/v) agarose gel 
electrophoresis with ethidium bromide and viewed under UV light. The bands of interest were 
excised from the gel and gel-purified as previously described. The barnase gene was removed 
from the Flexi™ vector under the same conditions as previously described. 
 
3.3.2 Ligation into Flexi™ Vector  
Each insert was ligated into the pFN2A Flexi™ vector. Ligation reaction was set up as to 
manufacturer’s instructions. Briefly, 10μl 2X Flexi™ ligase buffer(60mM Tris-HCl (pH 7.8 at 
25°C), 20mM MgCl2, 20mM DTT, 2mM ATP), 5μl acceptor Flexi™ vector (cut with SgfI 
and PmeI restriction enzymes), 4μl (±0.1μg/μl) viral gene product and 1μl T4 DNA ligase was 
incubated at 4°C overnight. The Flexi™ vector appends a GST fusion protein to the N-
terminal end of the expressed viral protein. 
 
3.3.3 Preparation of Chemically Competent E. coli, KRX Strain, and Transformation 
with Recombinant Plasmid 
KRX strain of competent E. coli was purchased from the manufacturers (Promega) and used 
to prepare subsequent cultures of competent cells. To prepare competent cells, cells were heat-
shocked at 42°C for 15 sec and allowed to recover in 450μl LB media at 37°C for 1 hour with 
shaking at 180rpm. Cells were subsequently plated on LB agar plates and grown for 16-20 
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hours at 37°C. Single colonies were inoculated into 100ml, ampicillin free LB media and 
incubated at 37°C, with agitation, for approximately 3 hours until the OD600 reached 0.35.  
Cultures were cooled to 0°C prior to harvesting by centrifugation at 4100rpm for 10 min. All 
subsequent work was done at 4°C and on ice. Cells were resuspended in 30ml ice cold 
solution of 80mM MgCl2 and 20mM CaCl2 and subsequently harvested for a second time by 
centrifugation. Pellets were again resuspended in 2ml ice cold 0.1M CaCl2 solution with 70μl 
DMSO and stored on ice for 15 min. An additional 70μl DMSO was added and gently mixed. 
50μl aliquots were prepared and instantly frozen in liquid nitrogen prior to storage at -80°C. 
 
Transformation reactions were set up as per manufacturer’s instructions. Briefly, KRX 
cells were removed from -80°C freezer and thawed on ice, to which 5μl ligation product was 
added and returned to ice for 5-10 min. The cells were then heat-shocked for 15-20 sec at 
exactly 42°C and returned to ice for 2 min. 450μl LB broth, without ampicillin, was added to 
each transformation reaction and incubated for 60 min at 37°C with shaking at 180rpm. 
Following which, cells were harvested at 2000rpm for 10 min and resuspended in 200μl LB 
broth, of which 100μl was plated on LB plates containing 1μg/ml ampicillin. Plates were 
incubated at 37°C for 16-20 hours. Single colonies were then picked and innoculated into 
terrific broth and corresponding PCR mix. Cultures were incubated at 37°C for 14 hours and 
PCR results were used to select cultures with correct insert. Cultures were stored in glycerol 
stocks at -80°C. If colony PCR was not adequate to identify cultures with correct vector 
construct, the plasmids were isolated using the mini-prep technique and constructs were later 
identified by either PCR or restriction, using SgfI and PmeI restriction enzymes, of the vector. 
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3.4 Expression of Full-Length SARS-CoV and HCoV-NL63 N and Deletion Mutants in 
E. coli 
3.4.1 Autoinduction 
The autoinduction protocol as described by Schagat et al. (2008) utilizes glucose and 
rhamnose to tightly control the T7 RNA polymerase gene via a rhamnose promoter (rhaPBAD) 
(Schagat, Ohana et al. 2008), which is  inhibited by the metabolites of glucose via a cyclic 
AMP (cAMP) pathway (Holcroft and Egan 2000). Glucose may therefore be used to inhibit 
pre-induction protein expression, where rhamnose will induce protein expression but only 
once the glucose is completely metabolized from the culture media. 
An early autoinduction protocol was utilized where glycerol stocks of SARS-CoV N-
Flexi, N1-Flexi, N2-Flexi, N3-Flexi and N4-Flexi were inoculated into a starter culture of 
10ml LB media and incubated at 37°C for 14 hours with shaking at 180rpm. Starter cultures 
were diluted 1:100 into LB media supplemented with 0.05% (w/v) glucose and 0.1% (w/v) 
rhamnose and incubated at 37°C with shaking at 180rpm. Samples of 50ml were taken at 8 
and 24 hours and harvested by centrifugation at 6000rpm for 15min at 4°C to prevent protein 
degradation. Dry cell pellet was frozen at -80°C until further use. We were unable to detect 
any protein expression and therefore chose to modify the expression protocols as follows. 
 
3.4.2 Induction at specific OD600 reading with fermentation at 37°C 
Glycerol stocks were inoculated into 10ml of LB media and incubated for 14 hours at 37°C 
with shaking at 180rpm. Starter cultures were diluted 1:100 into 100ml LB media and 
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incubated for approximately 4 hours when OD600 readings were taken. Once the culture 
reached an OD600 of 0.3-0.4 expression was induced by the addition of 0.1% (w/v) rhamnose. 
Cultures were incubated as previously described for 24 hours when cells were harvested by 
centrifugation at 6000rpm for 15min.Expression was detectable but however at a low 
concentration and therefore we further chose to modify the expression protocol by reducing 
the fermentation temperature to 25°C. 
 
3.4.3 Induction at specific OD600 reading with fermentation at 25°C 
The previous method was maintained until after induction of expression where the 
fermentation temperature was reduced to 25°C. Low yields of expressed proteins may indicate 
toxicity to the cell by the heterologous protein and therefore decreasing the fermentation 
temperature will slow the initial expression of the protein allowing the cell to acclimatize and 
thereby increasing final yields. We, however, were not able to detect any protein expression 
and therefore returned all fermentation temperatures to 37°C. 
 
3.4.4 Time course expression 
Expression protocols described in 3.4.2 were maintained where starter cultures were 
inoculated into 400ml LB media. Samples of 100ml were then taken at 5, 11, 18 and 24 hours 
post-induction to ascertain at which point expression is at its highest. Protein catabolism was 
noted following 5 hours post-induction and therefore for all subsequent expressions cells were 
harvested 5 hours following induction. 
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3.4.5 Large scale expression 
Due to the low levels of protein expression a large scale culture was necessary to obtain an 
ideal concentration for protein purification. The expression protocols described in 3.4.2 and 
3.4.4 were maintained where starter cultures were inoculated in 500ml LB media. Following 5 
hours post-induction cells were harvested as previously described. 
 
3.5 Protein Analysis 
3.5.1 Protein extraction and Preparation of Cell Lysates 
Following centrifugation each gram of cell pellet was resuspended by vortexing in 2ml of 
lysis buffer containing 1% (v/v) TritonX, 150mM NaCl, 10mM Tris(hydroxymethyl)-amino-
methane (Tris), 5mM EDTA and a protease inhibitor cocktail (Sigma). Table 3.2 describes the 
function of all constituents in the lysis buffer. Cells were subsequently lysed by sonication in 
an ice bath to prevent protein degradation. All subsequent work was done on ice or at 4°C. 
Following sonication, insoluble cell fraction was separated from soluble fraction by 
centrifugation at 14000rpm for 15 min. The soluble fraction was removed and stored at -20°C. 
The insoluble fraction was resuspended in 1ml lysis buffer by sonication as vortexing posed 
insufficient. 
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Table 3.3: Function of components of chosen cell lysis buffer. 
Compound Function 
TritonX Non-ionic detergent; improves solubility of GST fusion proteins and 
prevents aggregation of lysed cells. 
NaCl Provides an osmotic shock to cells 
Tris Interacts with lipopolysaccharides in the outer membrane of the cell and 
thereby increases permeability. 
EDTA Inhibits divalent cation-dependent proteases 
 
Protein expression was detectable in both the soluble and insoluble fraction of the cell 
and therefore several buffers containing chaotropic compounds, which were identified from 
the literature and known to increase protein solubility were used to increase solubility of the 
membrane bound fraction. All buffers are described in Table 3.3. None of the buffers used 
showed any ability to increase protein solubility and therefore lysozymes were introduced to 
the lysis buffer previously described in a final concentration of 0.1mg/ml. The insoluble 
fraction was incubated for 3 hours at room temperature on a rocker in the buffer containing 
lysozymes (Thermo Scientific). Subsequently samples were centrifuged at 14000rpm for 15 
min and the supernatant was removed and stored at -20°C. The pellet was further resuspended 
as previously described to ascertain whether any expressed proteins remained in the insoluble 
fraction.  
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Table 3.4: Buffers used to increase protein solubility from the membrane-bound fraction.  
 Description 
Buffer 1 2% (v/v) TritonX 
Buffer 2 BPer (20mMTris buffer ( pH 7.5) and proprietary additives) 
Buffer 3 20mM HEPES, 420mM NaCl, 2mM EDTA, 25mM MgCl2 and 0.1M DTT 
Buffer 4 1% (v/v) TritonX, 20mM HEPES, 420mM NaCl, 0.2mM EDTA, 1.5mM 
MgCl2, 1mM DTT, 5% (w/v) SDS, 33% (v/v) glycerol 
Buffer 5 1% (v/v) TritonX, 4M NaCl, 160mM Tris, 40mM Imidazole, 6M GuHCl 
Buffer 6 1% (v/v) TritonX, 150mM NaCl2, 5mM EDTA, 10mM Tris, 1.5% (w/v) N-
Lauroylsarcosine, 
 
3.5.2 SDS-Polyacrylamide Gel Electrophoresis and Coomassie Staining 
A 3% stacking and a 12.5% separation SDS-PAGE gel was used to separate proteins in a bio-
rad system. Electrophoresis was run at 15mA/gel for 80min in a Tris-glycine SDS running 
buffer (25mMTris, 192mM Glycine, 0.1% (w/v) SDS (pH 8.3)) The SDS-PAGE gel was then 
either stained in Coomassie Brilliant Blue stain (40% (v/v) methanol, 10% (v/v) acetic acid 
and 0.025% (w/v) Coomassie Brilliant Blue R250) overnight, to identify all proteins 
expressed in the cell, or transferred to a nitrocellulose or PVDF membrane for Western Blot 
analysis, to identify the GST tag with the appended N-protein. Coomassie stain was removed 
using a coomassie destain solution (50% (v/v) methanol and 10% (v/v) acetic acid)and 
preserved in cellophane sheeting after treatment with gel drying solution (50% (v/v) methanol, 
10% (v/v) acetic acid and 10% (v/v) glycerol). 
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3.5.3 Western Blotting of Total Proteins  
For Western Blots, the proteins, separated by SDS-PAGE, were transferred to a nitrocellulose 
or PVDF membrane, where neither membrane had any noticeable preferential properties. Prior 
to transfer the nitrocellulose membrane was equilibrated in 20% (v/v) methanol and the PVDF 
in 100% (v/v) methanol. Proteins were transferred in transfer buffer (27mM 
tris(hydroxymethyl)-amino-methane, 191mM glycine and 20% (v/v) methanol) in a 
submersion system at 100V for 90min, after which, the membrane was blocked with a 5% 
(w/v) milk and 0.05% (v/v) tween 20 in PBS solution for 30min on a rocker. The membrane 
was then incubated at 4°C overnight on a roller in 3% (w/v) milk and 0.05% (v/v) tween 20 in 
PBS solution with the primary antibody, rabbitαGST, in a dilution of 1:5000. The membrane 
was then washed in a wash solution (0.05% (v/v) tween 20 in PBS) for 1 hour. The secondary 
antibody, peroxidase-labeled goatαrabbit, was added in a dilution of 1:5000 in fresh solution 
previously described and incubated at room temperature for 1 hour on a roller, following 
which, the membrane was washed in wash solution with subsequent addition of the peroxidase 
substrate. The presence of the GST-fusion protein was determined by colourimetric analysis.  
 
3.6 Purification of Recombinant Protein 
The MagneGST™ purification system utilizes the ability of reduced Glutathione to bind GST 
fusion proteins. Glutathione is therefore covalently linked to a paramagnetic particle to allow 
for isolation of the Glutathione-GST complex in a magnetic separation stand. 
The MagneGST™ particles were equilibrated by washing 3 times in the MagneGST™ 
binding/wash buffer (4.2mM Na2HPO4, 2mM K2HPO4, 140mM NaCl, 10mM KCl). Particles 
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were separated from the binding/wash buffer by placing tubes in the magnetic stand. 
Glutathione particles were then resuspended in 250μl binding/wash buffer and 25μl lysozyme 
treated pellet and 25μl soluble fraction was added and incubated at room temperature on an 
orbital shaker for 30min. Glutathione particles (now bound to GST fusion proteins) were 
isolated in the magnetic stand and washed 3 times in the binding/wash buffer. The particles 
were then resuspended in100μl elution buffer (50mM Glutathione, 50mM Tris-HCl) and 
incubated at room temperature for 30min on an orbital shaker. Particles were again separated 
in the magnetic stand and the supernatant (containing the purified GST fusion proteins) was 
removed and stored at -20°C. Purified proteins were subsequently quantified using the Quant-
IT™ protein assay kit with the Qubit™ Fluorometer. 
 
3.7 Cleavage of Fusion Tag and Purification of Native Protein 
For certain post-expression studies the native protein is required and therefore the full length 
GST fusion protein of SARS-CoV and HCoV-NL63 N was cleaved using ProTEV protease. 
ProTEV is a highly specific proteolytic enzyme that cleaves between glutamine and glycine or 
serine of the amino acid sequence ENLYFQG (Dougherty and Parks 1991; Carrington, 
Haldeman et al. 1993). The Flexi™ vector is engineered to contain this cut site upstream of 
the cloning site and downstream of the GST sequence. Cleavage of the GST affinity tag was 
done according to manufacturer’s instruction; briefly reactions were prepared in 100µl with 
5µl 20xProTEV buffer, 1µl 100mM DTT and 1µl 10UProTEV protease. Nuclease free water 
was replaced with purified fusion protein which was increased to a total volume of 93µl. The 
reaction was incubated for 3 hours at 30˚C.  
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Following incubation the sample was separated by SDS-PAGE as previously described 
and viewed using Coomassie Brilliant Blue R250. The GST affinity fusion tag and native N-
proteins were excised from the SDS gel and purified using an EzWay™ PAG protein elution 
kit (Koma Biotech). Gel slices were homogenized in the 2ml masher tubes provided and 
centrifuged at 14 000rpm for 2min. The homogenized gel slice was subsequently resuspended 
in equal volumes of elution buffer following which, centrifugation was repeated. The 
collection tube, containing the cleaved proteins, was then vortexed to resuspend the sample, 
which was transferred to a spin filter and centrifuged at 14 000rpm for 5min for the first 
recovery of cleaved proteins. For the second recovery the sample in the spin filter was 
resuspended in an equal volume of elution buffer and centrifuged again. The purified protein 
was transferred to a clean collection tube and stored at -20˚C. 
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4. Results 
4.1 PCR  
The N-gene of SARS-CoV was PCR amplified from a pXJHA40 vector and HCoV-NL63 was 
amplified from cDNA generated by RT-PCR of the viral RNA. The gene sizes, as determined 
by the accession number from NCBI, were as follows: SARS-CoV N: 1269bp; N1: 1134bp; 
N2: 567bp; N3: 567bp and N4: 378bp. Following PCR, the products were run on a 1% (w/v) 
agarose gel and viewed under UV light (Figure 3.1). The N-genes were identified as the 
correct size and gel excised for purification with a PCR gel Clean-Up kit (Promega). The viral 
genes were subsequently ligated into a pGEM
®
 vector and used to transform JM109 strain 
competent E. coli. 
 
Figure 3.1: PCR amplification of viral genes using primers described in table 3.1. Lane M: 100bp marker. 
Lane 1: SARS-CoV N-gene (±1200bp) amplified from pXJHA40 vector; Lane 2: HCoV-NL63 full length N-
gene (±1100bp) (N1); Lane 3: 5’ half of the HCoV-NL63 N-gene (±550bp) coding for the N-terminal fragment 
of the N-protein (N2); Lane 4: 3’ half of the HCoV-NL63 N-gene (±550bp) coding for the C-terminal fragment 
of the N-protein (N3); Lane 5: Middle ⅓ of the HCoV-NL63 N-gene (±400bp) coding for the middle fragment of 
the N-protein. Lane 1Kb: 1Kb marker. All genes represented in lanes 2-5 were PCR amplified from cDNA 
previously generated from reverse transcription of viral RNA. 
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4.2 Colony PCR of JM109 Competent E. coli 
As identification of the amplified gene by size chromatography is not completely accurate, the 
viral genes were subsequently ligated into the pGEM
®
 T-easy vector for sequencing with M13 
primers, which will also allow for identification of any base pair mutations. Following ligation 
into pGEM
® 
T-easy vector, JM109 competent E. coli was transformed with the plasmid. The 
transformed cells were inoculated onto LB-agar plates and incubated O/N at 37°C after which, 
single colonies were selected and inoculated into LB-media and corresponding PCR mix. 
The colony PCR allowed for identification of successfully ligated vectors and 
transformed cells (Figure 3.2). PCR reactions were viewed on a 1% (w/v) agarose gel under 
UV light and results were used to select cultures with correct gene constructs. Successfully 
transformed cells were stored in glycerol stocks at -80°C.Plasmids were extracted from 
JM109 cells and used for sequencing which was conducted by Inqaba Biotech. Forward and 
reverse sequences were aligned using multiple sequence alignment with ClustalX (Version 
2.0.12) and viewed in GeneDoc (Version 2.7.000). For results please refer to appendix 1-5. 
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Figure 3.2: Detection of viral genes in JM109 competent E. coli transformed with pGEM
®
 vector 
previously ligated with viral genes. Genes were detected using PCR with primers described in Table 3.1. 
(A) Lane M: 100bp marker; Lane 1: Blank; Lane 2: Negative control using all primers described in Table 3.1; 
Lanes 3-9: Amplification of SARS-CoV N. (B) Lane M: 100bp marker; Lane 1-3: Amplification of N1 gene. 
Lane 4: Unsuccessful amplification of the N1 gene; Lanes 5-8: Amplification of the N2 gene; Lanes 9-12: 
Amplification of the N3 gene; Lanes 13-16: Amplification of the N4 gene. All positive amplifications indicate 
successful ligation into the pGEM® vector with subsequent transformation of JM109 competent E. coli with the 
ligation product. 
 
4.3 EcoRI Digest of pGEM
®
-N 
As a second confirmatory step, prior to sequencing, the insert was removed from the vector 
with the use of EcoRI restriction enzymes (Figure 3.3). EcoRI recognition sites are located up- 
and down-stream of the cloning site allowing for easy removal of the insert. 
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Figure 3.3: Confirmation of successful ligation by restriction of the pGEM
®
 vector with EcoRI enzymes. 
Lane M: 100bp marker; Lane 1: SARS-CoV N-gene; Lane 2: N1 gene; Lane 3: N2 gene; Lane 4: N3 gene; Lane 
5: N4 gene. The presence of the correct gene sizes is a second indication of successful ligation and 
transformation. 
 
4.4 SgfI and PmeI Restriction 
Once the presence of viral genes was confirmed by sequencing, the inserts were removed by 
restriction with the Flexi™ restriction enzymes, SgfI and PmeI. To ensure vectors were 
completely cut by both enzymes, the reaction was viewed on a 1% (w/v) agarose gel under 
UV light (Figure 3.4) and viral genes were identified by their correct sizes. Bands were then 
excised from the gel, purified and ligated into the Flexi™ protein expression vector. KRX 
competent cells were then transformed using the newly synthesized viral gene-vector 
construct. 
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Figure 3.4: Restriction of the pGEM
®
 vector, with SgfI and PmeI, isolated from JM109 competent E. coli 
to remove viral genes. Lane M: 100bp marker; Lane 1: SARS-CoV N-gene; Lane 2: N1 gene; Lane 3: N2 gene; 
Lane 4: N3 gene; Lane 5: N4 gene. All viral genes have an appended 5’ SgfI and a 3’ PmeI restriction site to 
allow for digestion with respective enzymes and subsequent ligation into the Flexi™ vector. Note: Upper vector 
is linear where the lower vector is supercoiled. 
 
4.5 Colony PCR of KRX Competent E. coli 
To confirm ligation of the Flexi™ vector with the viral genes and the transformation of the 
KRX cells, single colonies were inoculated into a culture and corresponding PCR reaction and 
viral genes were amplified as previously described. Results were again used to select 
successfully transformed colonies (Figure 3.5). As colony PCR can result in false positives 
and negatives a second sequencing step is critical where the T7 terminator (reverse) primer 
was used. The T7 promoter (forward) primer was not utilized as the T7 recognition site is 
upstream of the GST tag sequence resulting in the polymerase not reading sufficiently into the 
ligated open reading frame. For these constructs reverse sequences were seen as sufficient to 
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confirm ligation and reference can be made to pGEM
®
 sequences to confirm entire gene 
sequence. Please refer to appendix 6-10 for sequencing results using the T7 terminator primer. 
 
Figure 3.5: Colony PCR of KRX competent E. coli previously transformed with Flexi™ vector ligated with 
viral genes. Colony PCR was performed with primers described in Table 3.1 and used as confirmation of 
successful transformation and ligation.(A) Lane M: 100bp marker; Lane 1: Positive control for SARS-CoV N 
where pGEM
®
 vector ligated with the SARS-CoV N-gene was used as a control template (for all subsequent 
positive controls pGEM® vector, ligated with the respective viral gene, was used); Lanes 2 and 3: amplification 
of the SARS-CoV N-gene; Lane 4: Positive control for N1-gene; Lanes 5 and 6: Amplification of the N1-gene. 
(B) Lane M: 100bp marker; Lane 1: Positive control for the N2-gene; Lanes 2 and 3: amplification of the N2-
gene; Lane 4: Positive control for the N3-gene; Lanes 5 and 6: Amplification of the N3-gene; Lane 7: Positive 
control for the N4-gene; Lanes 8 and 9: Amplification of the N4-gene. All successful amplifications of viral 
genes represent colonies, picked from agar plates, which were successfully transformed with the respective 
Flexi™-viral gene construct. 
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4.6 Bacterial Expression and Purification of Recombinant Viral Proteins 
Figure 3.6 depicts the different regions of the N-protein which were expressed. The expression 
protocol which was adopted included subculturing of starter cultures into an expression 
culture in a dilution of 1:100. Cultures were grown for approximately 4 hours until an OD600 
of 0.3-0.4 was reached when expression was induced with the addition of 0.1% (w/v) 
rhamnose. OD600of cultures are shown in table 3.4. Cells were harvested 5 hours post-
induction and lysed using protocols previously described. 
 
Table 3.5: OD600 (mg/ml) of cultures after time specified. 
Construct Starter Culture 5 hours post-induction 
Uninduced 0.63 0.71 
SARS-CoV N 0.57 0.40 
N1 0.62 0.44 
N2 0.57 0.56 
N3 0.58 0.61 
N4 0.62 0.75 
 
As shown in Table 3.4 the expression of the viral-GST fusion proteins decreased the 
OD600 readings in comparison to the uninduced control. This indicates possible toxicity of the 
proteins to the bacterial cell, which would explain the difficulty in modifying protocols for 
successful expression of the viral proteins. Expression of the heterologous proteins was 
detected by Western Blot in both the cytoplasmic and membrane bound fractions of the cell 
(Figure 3.7). The presence of expressed proteins in the insoluble fraction indicates either 
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formation of inclusion bodies or interaction of the protein with the bacterial membrane. The 
pellet was therefore treated with chaotropic agents known to disassemble inclusion bodies 
allowing for detection in the soluble fraction. Following treatment there was, however, no 
increase in the proportion of soluble proteins, which indicates possible interactions with the 
bacterial cell membrane. 
 
 
Figure 3.6: Schematic description of SARS-CoV and HCoV-NL63 N-proteins and recombinant mutants of 
N2, N3 and N4. Numbers indicate amino acid positions. 
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Figure 3.7: Detection of SARS-CoV and HCoV-NL63 N-proteins by Western Blot with peroxidase labeled 
antibodies against the GST fusion protein. (A) Proteins expressed in membrane-bound, insoluble fraction 
of the cell. (B) Cytoplasmic expression of soluble fusion proteins.(A) Lane M: Prestained molecular weight 
protein marker; Lane 1: Uninduced control to determine any background or cellular protein expression where 
cultures of N2 were used; Lane 2: Expression of the 73.02kDa GST-SARS-CoV N fusion protein; Lane 3: 
Expression of the 69.6kDa GST-N1 fusion protein; Lane 4: Expression of the 48.51kDa GST-N2 fusion protein; 
Lane 5: Expression of the 47.9kDa GST-N3 fusion protein; Lane 6: Expression of the 41.01kDa GST-N4 fusion 
protein. Lane order is maintained for Figure 3.7B. 
 
To test the hypothesis that the heterologously expressed viral-fusion proteins interact with 
bacterial cell wall, the cell pellet was treated with lysozymes in the same buffer used for lysis. 
Following 3 hours of treatment with lysozymes a large proportion of the heterologous proteins 
were released to the soluble portion (Figure 3.8). As lysozymes are known to digest the 
peptidoglycan layer of the bacterial cell wall, and as treatment was carried out following lysis 
by sonication, it indicates that the N-proteins interact with the bacterial cell wall during 
synthesis. This may provide a possible mechanism for toxicity as shown with the envelope 
protein of SARS-CoV, which is known to increase membrane permeability and subsequently 
lead to cell lysis (Liao, Lescar et al. 2004). 
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Figure 3.8: Digestion of cellular membranes using lysozymes to release membrane-bound, insoluble 
proteins. (A) Western Blot representing proteins which remained in the insoluble fraction following 
digestion with lysozymes. (B) Proteins made soluble following digestion with lysozymes. (A) Lane M: 
Prestained molecular weight protein marker; Lane 1: Uninduced control; Lane 2: GST-SARS-CoV N; Lane 3: 
GST-N1; Lane 4: GST-N2; Lane 5: GST-N3; Lane 6: GST-N4. Lane order is again maintained for 3.8B. 
 
The presence of a band in Figure 3.7B and 3.8B, in the uninduced lane 1, with the same 
molecular weight as N2 indicates that the Flexi™ vector system is susceptible to leaky 
background expression via the T7 promoter, which is in strong contradiction that the T7 RNA 
polymerase is tightly controlled by rhamnose induction via the T7 promoter.  Following 
isolation of the heterologously expressed, viral-GST fusion proteins purification of the 
cytoplasmically expressed and lysozyme treated membrane fraction were done with the use of 
the MagneGST™ purification system (Figure 3.9). The inability to purify N4 may be due to 
the low yield of expression and the low proportion released by lysozyme digestion. Final 
concentration of purified proteins is represented in Table 3.5. 
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Table 3.6: Concentration of purified proteins in mg/ml. 
Construct Concentration (mg/ml) 
SARS-CoV N-GST 0.44 
N1-GST 0.11 
N2-GST 0.24 
N3-GST 0.17 
N4-GST 0.00 
 
 
Figure 3.9: (A) Western Blot detection and (B) Coomassie stain of GST fusion viral proteins, purified 
using the MagneGST™ purification system.(A) Lane M:Prestained molecular weight protein marker; Lane 1: 
Purified GST-SARS-CoV N; Lane 2: Purified GST-N1; Lane 3: Purified GST-N2; Lane 4: Purified GST-N3; 
lane 5: Absence of GST-N4 indicates an inability to purify, possibly due to a low concentration of expressed 
proteins. Lane order is maintained for 3.9B, where the protein marker has been replaced with an unstained 
molecular weight protein marker. 
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4.7 Cleavage of Fusion Tag 
The GST affinity tag of the heterologously expressed SARS-CoV and HCoV-NL63 full length 
N-proteins was successfully cleaved using ProTEV protease. The cleavage yielded a ~27kDa 
GST protein and the ~46kDa SARS-CoV N-protein, with the HCoV-NL63 N-protein 
presenting at approximately the same size. The size of the HCoV-NL63 N-protein is slightly 
bigger than the predicted size of 42.26kDa (Figure 3.10). 
 
 
Figure 3.10: Cleavage of the GST affinity tag from SARS-CoV and HCoV-NL63 full length N using 
ProTEV protease. Lane M: Prestained molecular weight protein marker; Lane 1: Uncleaved SARS-CoV N; 
Lane 2: SARS-CoV N with GST cleaved; Lane 3: UncleavedHCoV-NL63 N; Lane 4: HCoV-NL63 N with GST 
cleaved.  
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5. Discussion and Conclusion 
The Flexi™ vector system has proven to be a suitable method for the heterologous expression 
of the SARS-CoV and HCoV-NL63nucleocapsid proteins, however, not without several 
drawbacks including the inability to purify the expressed N4 protein, possibly through low 
levels of synthesis. The inability to detect purified N4 through quantification, Western Blot 
and coomassie may be due to the disordered nature of this region within the protein, and 
therefore a lack of a tertiary structure, leading to possible catalytic breakdown through the 
exposure of all active sites. This can be supported in that the full length N-protein, which also 
contains the full disordered region, yielded the lowest concentration of expressed proteins in 
comparison to the N- and C-terminals, which only contained their respective halves. This 
region will therefore have to be expressed in a cell-free system to alleviate the possibility of 
cellular degradation. 
The instability of the coronavirus N-proteins has also been reported for SARS-CoV 
(Wang, Wu et al. 2004), 229E (Tang, Wu et al. 2005) and IBV (Fan, Ooi et al. 2005). 
Intracellular degradation has been reported by Fan et al. (2005), where bacterial proteases 
were found to be responsible. Fan et al. (2005) however utilized a BL21 protein expression 
system, which, when compared to KRX, is much less protease deficient and therefore a lower 
degree of protein degradation should be seen in the KRX system. Autolytic degradation has 
also been reported to occur at 4°C where the purified N-protein of IBV was found to degrade 
rapidly (Fan, Ooi et al. 2005). With our findings it may indicate that this degradation is 
directed via the middle, disordered region, corroborated by the fact that degradation yields the 
C-terminal spanning region from amino acid 169-422 of the 229E N-protein (Tang, Wu et al. 
2005), indicating that cleavage does occur in the middle, disordered region. With these 
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findings it should be advised that all protein storage should be between -80 and -20°C, as we 
could not detect any autolytic degradation at -20°C. 
Expression of a considerable fraction of the heterologous proteins in the insoluble 
fraction is another cause for concern as this will result in a lower yield of purified proteins. 
Solubilizing this fraction then becomes crucial to obtain a high enough protein concentration 
to perform post-expression studies. Research into the development of solubilizing techniques 
has increased over the years with several approaches being adopted, however, each method is 
dependent on the protein expressed and trial and error is the only approach available to 
determine which technique is effective, making solubilization a time consuming, labour 
intensive and often expensive procedure. Following solubilization, the protein is often 
incorrectly folded due to chaotropic agents used to denature the protein or inappropriate 
environment provided by the cell and therefore refolding strategies, which are also dependant 
on the expressed protein, becomes the next time-consuming cause for concern. Various 
techniques have been proven to be effective in refolding denatured proteins including 
controlled air oxidation (Menzella, Gramajo et al. 2002), co-expression of molecular 
chaperones (Hannig and Makrides 1998) and altering fermentation conditions with the 
addition of 3% ethanol, which increases the expression of heat shock proteins known to act as 
chaperones (Steczko, Donoho et al. 1991). These approaches are however trial and error and 
can therefore pose very time consuming. 
We have improved the proportion of soluble proteins by treating the insoluble fraction 
with lysozymes, and as this technique has no impact on the expressed protein, as it purely 
digests the peptidoglycan layer of the bacterial cell wall, there is no need for in vitro refolding 
of the protein for any bio-activity. As treatment with lysozymes is a relatively inexpensive and 
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rapid approach to solubilizing insoluble proteins it should be adopted as the first technique 
prior to treatment with chaotropic agents and other time consuming solubilizing methods. 
However, lysozymes are not capable of solubilizing inclusion bodies and therefore should 
only be used to ascertain interaction with the cell wall. 
Through OD600 readings it was identified that both the SARS-CoV and HCoV-NL63 
N-proteins cause a reduction in cell density, in comparison to an uninduced control, with 
SARS-CoV N resulting in the greatest reduction and N4 resulting in no reduction. These 
results are expected as SARS-CoV N is the highest expressed of the 5 heterologous proteins 
and N4 being barely detectable. The reduction in cell density indicates possible toxicity of the 
N-protein to the bacterial expression system, most likely through its interaction with cellular 
membranes as has been shown for the envelope (E) protein of SARS-CoV. The E-protein is 
known to slow E. coli (BL21) growth by increasing membrane permeability and subsequently 
leading to cell lysis. This lysis would allow for new progeny virus to spread to neighboring 
cells, thereby continuing viral lifecycle (Liao, Lescar et al. 2004).The SARS-CoV N-protein 
also induces apoptosis in COS-1 cells in the absence of growth factors (Surjit, Liu et al. 2004). 
These results may therefore indicate a possible pathological mechanism coronaviruses use to 
induce disease. As E. coli does not undergo any form of apoptosis it would be impossible to 
confirm toxicity of the N-protein but these results do lead to more interesting research in a 
mammalian system. 
Toxicity induced by heterologous proteins to the host cell, resulting in a decrease in 
growth rate, has also been shown to increase plasmid loss and therefore a later reduction in 
overall protein yield (François 1999). For these reasons it is important to conduct expressions 
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in a large scale culture to ensure a sufficient final protein yield to conduct post-expression 
studies. 
When the uninduced N2-Flexi construct was used as a control to ascertain any 
ambiguity with cellular expression it was noted that there was a significant level of 
background expression of GST-N2, as bands of similar size were only seen in the test lane for 
GST-N2. When a foreign gene is expressed in a host cell it produces many metabolic stresses 
to the cell by utilizing the cell’s resources and possibly producing metabolites that are toxic to 
the cell. This must especially be avoided in the logarithmic phase to allow for stabilization of 
the host and the introduced plasmid (Glick 1995). Background expression should be avoidable 
with the use of strong promoters to enable the ability to turn “on” and “off” gene expression, 
however, the T7 promoter, used in this study, has been shown to be a leaky promoter 
(Weickert, Doherty et al. 1996) thereby producing a metabolic burden to the host cell and 
subsequently reducing cell growth and final yield of expressed protein. 
Given the several problems posed by the Flexi™ vector system it still remains a 
suitable method for the cloning and expression of the SARS-CoV and HCoV-NL63 N-
proteins with the generation of truncated clones of the N- and C-terminals of HCoV-NL63 N. 
These heterologously expressed proteins will now provide the basis for several post-
expression studies including characterizing the regions responsible for eliciting an immune 
response and identifying antibody cross-reactivity between coronavirus species. Various other 
studies, outside the scope of this thesis, including identifying the regions involved in RNA 
binding and dimerization of the HCoV-NL63 N-protein and antibody production in a murine 
model can also be conducted. 
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1. Abstract 
Shortly after the SARS-CoV outbreak, another human coronavirus (HCoV-NL63) was 
identified. This virus has since been shown to have a worldwide distribution and is 
continuously circulating in the human population. The primary function of the coronavirus 
nucleocapsid (N) protein is the formation of the ribonucleocapsid core by interacting with 
viral RNA during virus assembly. The nucleocapsid protein is highly antigenic and highly 
expressed during viral infection making it suitable for the development of diagnostic assays.  
 
In this study, an antibody-capture ELISA assay was developed using recombinant 
clones of the full length HCoV-NL63 (N1: aa 1-378) N protein, as well as truncated clones 
corresponding to the N- (N2: aa 1-189) and C-terminals (N3: aa 190-378) of the HCoV-NL63 
N-protein. The ELISA was then used to screen human serum samples (15 HCoV-NL63 
seropostive) to identify the antigenic epitopes of N.  
 
Serum antibodies detected HCoV-NL63 N, but cross-reactivity between SARS-CoV N 
and the serum HCoV-NL63-specific antibodies was also observed. We could not identify the 
antigenic epitope as both the N- and C-terminal reacted with equal intensity. This could be an 
indication of: 1) the presence of several immunogenic sites on both the N- and C-terminal 
domains, or 2) the division of one immunogenic site between the two fragments. Some cross-
reactivity to another coronavirus N protein was observed and the assay needs to be optimized. 
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2. Introduction 
Coronaviruses (CoVs) are enveloped viruses in the order Nidovirales. The Coronaviridae 
family is composed of single-stranded, positive sense RNA viruses, with genomes ranging in 
size from 25 to 30 kb (He, Dobie et al. 2004). CoVs are responsible for a variety of diseases in 
animals resulting in respiratory, enteric, nephritic, hepatic and neurological conditions with a 
varying degree of severity (McIntosh 2005; Lau, Li et al. 2010). In humans, coronaviruses 
result in approximately 10-30% of upper respiratory tract infections, which commonly 
manifests as common cold-like symptoms. Until the discovery of the Severe Acute 
Respiratory Syndrome coronavirus (SARS-CoV), it was thought that CoV infections were not 
severe. SARS-CoV however, resulted in ~10% mortality of infected patients globally. In fact, 
mortality was as high as 40% in certain population groups (Surjit, Kumar et al. 2005) and 
between 43-55% in people older than 60 years (Marra, Jones et al. 2003). 
Following the outbreak of SARS it was shown that CoVs are capable of undergoing 
recombination events resulting in a more lethal form of the virus. This ignited a new interest in 
the detection and characterization of previously unidentified respiratory viruses, which led to 
the later discovery of HKU1 (Woo, Lau et al. 2005) and HCoV-NL63 (van der Hoek, Pyrc et 
al. 2004). HCoV-NL63 presents clinically as the common cold with symptoms including 
fever, cough, sore throat and rhinitis (Chiu, Chan et al. 2005; Ebihara, Endo et al. 2005; 
Kaiser, Regamey et al. 2005; Suzuki, Okamoto et al. 2005; Vabret, Mourez et al. 2005; van 
der Hoek, Pyrc et al. 2006; Han, Chung et al. 2007; Kuypers, Martin et al. 2007; Smuts 2008; 
Wu, Chang et al. 2008; Talbot, Crowe et al. 2009; Fielding 2011). Prevalence of infection 
with HCoV-NL63 is highest in the age group 0-5 years old and is also frequently observed in 
patients who are immunocompromised and the elderly (van der Hoek, Pyrc et al. 2006). 
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As all human coronaviruses (HCoV) currently in circulation present with similar clinical 
symptoms, the diagnosis of individual HCoVs based on symptomatic presentation is virtually 
impossible. Currently the diagnosis of HCoV-NL63 is largely based on genetic markers 
identified by PCR and real time PCR (Bastien, Robinson et al. 2005; Koetz, Nilsson et al. 
2006; Brittain-Long, Nord et al. 2008). Real time PCR is, however, expensive and requires a 
high level of competence from the user and is therefore not suitable for use in poorly equipped 
diagnostic facilities, which are common in third world countries. The development of an 
affordable and reliable diagnostic antibody capture enzyme linked immunosorbent assay 
(ELISA) - for the direct detection of viral antigens - would therefore be beneficial in such an 
environment.  
Since N is highly antigenic, abundantly expressed during viral infection (Timani, Ye et 
al. 2004) and detectable as early as the 1
st
 day after infection (Che, Hao et al. 2004), it is a 
suitable target for the development of such a diagnostic assay (Lehmann, Wolf et al. 2008). 
Early detection of infection using serodiagnosis, however, is unreliable as seroconversion 
takes a median time of 17-19 days (Che, Qiu et al. 2004; Woo, Lau et al. 2004). Also, the use 
of serodiagnosis in the detection of HCoVs is even less reliable as HCoVs often cause 
reinfection throughout life (Sastre, Dijkman et al. 2011), making detection of serum antibodies 
to current infections, without detecting prior infections, impossible. For these reasons the 
direct detection of viral proteins would serve more reliable.  
In this pilot study, we have developed an ELISA using recombinant N-proteins of 
HCoV-NL63 and SARS-CoV expressed in a bacterial system. Truncated clones corresponding 
to the N- and C-terminals of the HCoV-NL63 N were also synthesized to identify the 
antigenic epitope of the protein. The inclusion of SARS-CoV N as a control would allow us to 
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identify any cross-reactivity between coronavirus species, which is important for determining 
the specificity of the assay. HCoV-NL63-positive patient sera (n=15) were screened to 
determine the sensitivity and specificity of our assay in detecting anti-N-IgG serum antibodies 
against HCoV-NL63 N. Serum from all patients screened cross-reacted with the SARS-CoV 
N-protein. There was also no identifiable antigenic epitope as both the N- and C-terminals of 
the N-protein reacted equally with patient serum.  
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3. Materials and Methods 
3.1 Patient serum samples 
A panel of 17 serum samples collected from young adults in Germany was used in this study. 
The samples included: 1) 15 samples previously confirmed to be HCoV-NL63 seropositive; 2) 
one confirmed HCoV-NL63 seronegative sample; and 3) one SARS-CoV seropositive sample 
(this serum sample was not previously confirmed HCoV-NL63 seronegative). All ELISA 
screens were done at University of Bonn, Germany. 
 
3.2 ELISA 
Expression of recombinant proteins has been described in detail in Chapter 3. Proteins were 
quantified and standardized to 3ug/ml in coating buffer (0.1M NaHCO3). Each well of a 
Maxisorb microtitre plate (Thermo Scientific) was coated with 50ul of recombinant protein 
(Table 4.1) and incubated overnight at 4°C.  
 
Plates were washed 5 times with 300ul washing buffer (PBS containing 0,1% (v/v) 
Tween) and blocked with 5% (w/v) fat-free milk in washing buffer for 1 hour at room 
temperature. Plates were subsequently washed 5 times as previously mentioned. Serial 
dilutions (1:100 to 1:6400) of the appropriate primary antibody (rabbit-anti-N used in the 
positive control; human sera when screening patient samples or rabbit-anti-GST for coating 
controls) in 1% (w/v) fat-free milk in PBS-Tween was incubated for 2 hours at room 
temperature. Plates were again washed 5 times, following which peroxidase-labeled goat-anti-
rabbit or human-anti-IgG in a dilution of 1:4000 with PBS-Tween and 1% (w/v) milk, was 
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added to respective samples and incubated for 1 hour at room temperature. Plates were again 
washed 5 times and the reaction was viewed after addition of TMB, peroxidase substrate. 2M 
sulphuric acid was used to stop the reaction after 3-5 min. Absorbance readings were done at 
450/630nm with a Glomax (Promega) 
 
Table 4.1: Recombinant proteins included in the study. 
Construct Name Description 
N/A
# 
GST tagged protein control to confirm plates were adequately coated 
GST GST only to confirm antigenicity detected was not directed against the 
fusion protein 
SARS-N SARS-CoV full length N (aa 1-423) 
N1 HCoV-NL63 full length N (aa 1-378) 
N2 N-terminal half of the HCoV-NL63 N (aa 1-189) 
N3 C-terminal half of the HCoV-NL63 N (aa190-378) 
#
N/A – Not applicable 
 
3.3Statistical Analysis 
ELISA results were taken at a wavelength of 450nm and 630nm. The readings at 630nm were 
subtracted from readings at 450nm to give results without background. An average of the 
blank or no-coat lane was taken and this was subtracted from the results without background. 
These readings were then used for statistical analysis. 
The sensitivity and specificity of the N-protein in detecting anti-N-IgG antibodies was 
determined with the use of receiver operating characteristic (ROC) curve analysis from 
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MedCalc Ver 12.0.0.0 (Zweig and Campbell 1993). When screening the HCoV-NL63 
seropositive patients, the HCoV-NL63 N-protein was used as the positive control/experiment, 
and the SARS N-protein was used as the negative control. A statistical difference (P<0.05) 
between the N2 and N3 construct would indicate a preferential immunogenic epitope. We 
therefore used a paired sample ANOVA, or T-test, from MedCalc Ver 12.0.0.0 to calculate the 
P-value. 
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4. Results 
A positive control using rabbit anti-N-IgG against the HCoV-NL63 N-protein showed, as 
expected, reaction with the HCoV-NL63 N-protein, indicating sensitivity of the assay. The 
rabbit IgG also failed to detect any significant levels of the SARS-CoV N-homologue (Figure 
4.1). These results indicated that the HCoV-NL63 N is both sensitive and specific in reacting 
with anti-N serum antibodies generated in rabbits and can therefore be used to screen patient 
serum. Rabbit anti-N-IgG was generated against a peptide in the N-terminal domain and 
therefore these results cannot be used to identify the antigenic epitope. A negative control, 
obtained from a confirmed HCoV-NL63 seronegative serum sample, also revealed no 
reaction, further indicating specificity of the assay (Figure 4.2). 
 
Figure 4.1: Detection of rabbit anti-N-IgG antibodies using heterologously expressed N-proteins. Results 
are represented as serial dilutions. Numbers 100-6400 represented serial dilutions from 1/100 to 
1/6400 respectively. Legend on the right indicates the heterologously expressed protein used to 
detect anti-N-IgG. Results indicated that antibodies generated in rabbits against a peptide in the N-
terminal of the HCoV-NL63 N-protein are both sensitive and specific as it was only detected by HCoV-
NL63 N and not SARS-CoV N. 
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Figure 4.2: ELISA using a confirmed negative patient serum. Results showed no non-specific binding with 
HCoV-NL63 negative serum. 
 
When patient serum was screened all HCoV-NL63 positive patient sera reacted 
positively, as expected, with the full length N1 protein. Patient serum also, however, showed 
cross-reaction with the SARS-CoV N-protein but with a lower intensity in majority of patient 
sera. We therefore included a SARS-CoV positive serum control to differentiate between 
cross-reactivity and detection of SARS-CoV N-antibodies. The results revealed that both 
SARS-CoV and HCoV-NL63 N-proteins reacted with similar intensity at a dilution of 1:100 
with SARS N decreasing with the concentration of primary antibody. In our previously 
confirmed SARS-CoV positive serum, the results indicated that the patient has previously also 
been exposed to HCoV-NL63, with HCoV-NL63 N eliciting a stronger immune response in 
comparison to SARS-CoV N, or it indicated that the SARS-positive patient serum was also 
capable of cross reaction with the HCoV-NL63 N-protein. These findings can, however, not 
be confirmed in this study and therefore requires additional research (Figure 4.3). ROC curve 
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analysis indicated that the N-protein is 100% sensitive and 46.7% specific at a criterion of 
>0.207 (Figure 4.4). 
 
 
Figure 4.3: Reaction of SARS positive serum with the heterologous expressed N-proteins. Results indicate 
that the patient was either previously exposed to HCoV-NL63 and has seroconverted or that anti-SARS-N-IgG is 
also capable of cross-reaction with the HCoV-NL63 N-protein. This is evident as all full length and truncated 
proteins reacted with the serum.  
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Figure 4.4: ROC curve analysis indicating the sensitivity and specificity of the N-protein in detecting 
serum antibodies. An ELISA with a perfect 100% sensitivity and specificity will have a diagonal line from the 
bottom left to top right corner, represented by the dashed line. Each sensitivity reading has a corresponding 
specificity reading. At the most valid criterion of >0.207 the ROC curve shows that the N-protein is 100% 
sensitive but only 46.7% specific in detecting anti-N-IgG antibodies. 
 
With the exception of patient 1, all patients showed low levels of cross-reaction with 
the GST tag indicating that the antigenicity detected was not against the GST fusion protein. 
To identify the antigenic epitope of the HCoV-NL63 N-protein, the N2 and N3 constructs 
were analyzed using a paired sample ANOVA, or T-test, to identify any significant difference 
between the regions. A P-value of 0.37 indicated that the two constructs are not significantly 
different and therefore neither the N- or C-terminal was preferentially immunogenic. We were, 
therefore, unable to detect the antigenic epitope of the HCoV-NL63 N-protein as both the N- 
and C-terminals reacted with equal intensity for majority of patient serums, showing that both 
the N- and C-terminal of the HCoV-NL63 N-protein are equally immunogenic. Some patients 
did, however, show a preference for either the N- or C-terminal, which may indicate infection 
with various isolates of HCoV-NL63 or a patient specific immune response (Table 4.2). 
 
 
 
 
Mapping the antigenic epitopes HCoV-NL63 N 
109 
 
Table 4.2: Patient antibody response to nucleocapsid constructs. The full length N-protein of 
HCoV-NL63 (N1) was taken as 100% response and therefore the remaining 3 constructs were 
represented as a percentage of N1. Values were taken from the standard curve where the response to 
GST was closest to 0.  
Patient HCoV-NL63 
Full Length N (N1) 
HCoV-NL63 
N-Terminal (N2) 
HCoV-NL63 
C-Terminal (N3) 
SARS-CoV 
Full Length N 
1 100 51.64 55.96 83.59 
2 100 67.30 57.62 32.93 
3 100 56.32 68.52 54.39 
4 100 72.22 72.22 63.77 
5
+ 
100 45.15 107.38 47.26 
6 100 52.45 78.39 52.45 
7 100 66.15 81.77 47.92 
8 100 55.56 60.00 55.56 
9 100 68.32 62.87 45.54 
10 100 64.79 74.18 57.75 
11 100 38.56 44.56 37.06 
12
+ 
100 64.15 100.00 40.39 
13 100 94.29 83.37 89.82 
14 100 16.22 33.33 25.23 
15
+  
100 106.02 38.07 46.02 
Average 100 61.27 67.88 51.98 
St. Dev. 0 21.34 20.97 17.27 
+Patients sera that showed a preference for either the N- or C-terminal of the HCoV-NL63 N 
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5. Discussion and Conclusion 
The diagnosis of individual HCoVs would provide fundamental information on the 
distribution of these viruses and their health related implications. HCoV-NL63 is currently 
understood to be an aetiological agent of the “common cold”. However, it has recently been 
shown that this virus commonly presents as co-infection with more serious “flu-viruses” 
(Esper, Weibel et al. 2005; Fielding 2011). This indicates that HCoV-NL63 could pose as a 
predisposing factor to allow infection by more lethal respiratory viruses. As acute lower 
respiratory tract infections have been shown to result in approximately 1.9 million deaths in 
children younger than 5 (Venter, Lassauniere et al. 2011), the diagnosis of these predisposing 
factors would prove pivotal in the initiation of adequate and correct treatment. 
The development of an ELISA for the detection of HCoV-NL63 antigens would 
provide an affordable, reproducible and reliable diagnostic assay. As the N-protein is highly 
antigenic and abundantly expressed during viral infection it would serve as a good marker in 
such an assay. In our study, however, the N-protein of SARS-CoV was detected by serum 
antibodies against HCoV-NL63. Although the N-protein showed 100% sensitivity in reacting 
with serum antibodies against HCoV-NL63, the high degree of cross-reactivity and low level 
of specificity raised questions as to the viability of using the N-protein as a diagnostic marker.  
Previous studies have also reported cross-reactivity between HCoV-OC43 and HCoV-
229E but failed to show cross-reaction between SARS-CoV and other known HCoVs 
(Lehmann, Wolf et al. 2008). Other reports however showed that two-way cross-reactivity 
between SARS-CoV and HCoV-229E, HCoV-NL63 and HCoV-OC43 is possible (Woo, Lau 
et al. 2004; Chan, Cheng et al. 2005; Che, Qiu et al. 2005) and that polyclonal antibodies from 
Group I coronaviruses including HCoV-229E, FIPV, Canine CoV and TGEV are capable of 
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reacting with SARS-CoV infected Vero cells (Sun and Meng 2004).  The same report however 
failed to show any cross-reaction between SARS-CoV and the Group II coronavirus to which 
HCoV-OC43 belongs (Sun and Meng 2004; Venter, Lassauniere et al. 2011). Using 
recombinantly expressed antigenic epitopes, the region of this cross-reaction was localized 
between amino acids 120-208 of the SARS-CoV N-protein and cross reaction mediated by the 
N-protein of HCoV-NL63 was localized to amino acids 1-39 of the N-terminal (Vlasova, 
Zhang et al. 2007). This cross-reactivity has been proposed to be either at an antigenic level, 
with cross-reaction occurring through cross-reactive epitopes, or at an antibody level, with the 
production of polyclonal antibodies (Chan, Cheng et al. 2005). In our previous chapter it was 
shown that the N-proteins of CoVs lack a high degree of homology and therefore it can be 
assumed that this cross-reaction is mediated by the production of polyclonal antibodies. We 
have also shown that polyclonal antibodies generated in rabbits did not have any degree of 
cross-reaction, which further indicates that human antibodies have a broader degree of antigen 
recognition. The spike protein is not capable of cross-reaction and has therefore been used as a 
confirmatory step (Woo, Lau et al. 2004; Vlasova, Zhang et al. 2007).  
Although the N-protein of coronaviruses show a high level of cross-reactivity, our 
study has shown that antibodies developed against the N-protein in rabbits has a lower degree 
of cross-reactivity. This is evident as our positive control using polyclonal rabbit-anti-N IgG 
was only able to detect the N-protein of HCoV-NL63 and not of SARS-CoV. A report by Che 
et al. (2005) also failed to detect any substantial level of cross-reactivity between HCoV-
229E, HCoV-OC43 and SARS-CoV when immune rabbit serum was used (Che, Qiu et al. 
2005). Identifying and directing detection against immunogenic epitopes will also increase 
specificity as the use of synthetic peptides, opposed to the full length protein, may show a 
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reduction in cross-reactivity (Sun and Meng 2004; Woo, Lau et al. 2004; Sastre, Dijkman et 
al. 2011). Several studies have also shown that the development of double antibody sandwich 
(DAS) ELISAs using a combination of monoclonal antibodies against the N-protein are highly 
sensitive and specific for the detection of HCoV-NL63, HCoV-229E (Sastre, Dijkman et al. 
2011) and SARS-CoV (Lau, Woo et al. 2004). 
We used truncated mutants corresponding to the N- and C-terminals of the HCoV-
NL63 N-protein to attempt to identify the antigenic epitope. The results, however, showed that 
both terminals reacted equally but to a lesser degree than the full length N-protein with sera 
from HCoV-NL63 positive patients. This indicated either the presence of several 
immunogenic peptides, or the division of a single peptide between both fragments. The middle 
and C-terminal (110-422 aa) of the N-protein are responsible for eliciting an immune response 
in SARS-CoV infection (Lee, Lee et al. 2008). If the N-protein of both HCoV-NL63 and 
SARS-CoV behave similarly, it may substantiate our latter claim that the immunogenic 
epitope of HCoV-NL63N is located in the middle fragment. Both SARS-CoV and HCoV-
NL63 have a long disordered region in the middle of their N-proteins which may expose this 
region to an immune response, explaining these results. This was also noted in a report 
showing that the disordered region of SARS-CoV and porcine CoV is responsible for 
mediating cross-reactivity (Vlasova, Zhang et al. 2007). The region of 122-422 of the N-
protein of SARS-CoV was more specific than the full length N-protein. Therefore narrowing 
down of the antigenic epitope may increase sensitivity and specificity of a diagnostic assay 
and therefore inclusion of this middle region might yield valuable information (Yu, Le et al. 
2007). However, due to the disordered nature of this region it poses difficult to express in a 
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bacterial system. Expression in cell-free system may be necessary to synthesize this region to 
determine its viability in a diagnostic assay. 
The N-protein of HCoV-NL63 has been shown to be sensitive in the detection of 
serum antibodies. It is also capable of cross-reaction with other coronaviruses and therefore it's 
use as a diagnostic marker is questionable. However, the production of monoclonal antibodies 
in rabbits using immunogenic peptides, possibly found within the middle, disordered region, 
rather than the use of the full length proteins, can greatly increase specificity.  
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The human coronavirus NL63 has been shown to be a clinically important virus, affecting 
mainly children, the elderly and immunocompromised. Infection mainly results in a mild, 
upper respiratory tract disease with symptoms including fever, cough, sore throat and 
rhinorrhoea. HCoV-NL63 also presents with more severe lower respiratory tract findings with 
infection being associated with bronchioloitis, pneumonia and croup. 
At a molecular level, the virus is assembled through the interaction of four structural 
proteins, namely the spike (S), membrane (M), envelope (E) and nucleocapsid (N) proteins. 
The N-protein of HCoV-NL63 is poorly characterized; however coronavirus homologues 
provide a good platform to base research on. The primary function of this protein is to interact 
with viral RNA to form the protective ribonucleocapsid core. For this particle to assemble, the 
N-protein has to undergo N-N homotypic interactions with subsequent interaction with viral 
RNA. The N-protein has also been shown to interact with the M-protein in the surface of the 
virion during viral assembly. Besides the primary structural role of the N-protein, it is also 
known to regulate viral transcription, translation and replication and certain cellular pathways. 
The N-protein is also highly phosphorylated and highly antigenic and has been shown to elicit 
a strong immune response. 
We have used various bioinformatic tools and molecular techniques to characterize the 
properties of this protein. Special attention has been paid to conserved regions of coronavirus 
N-homologues, identification of disordered regions and putative phosphorylation sites and, 
with the use of molecular tools, we have cloned and expressed the N-protein of HCoV-NL63 
and SARS-CoV. These heterologously expressed proteins have allowed us to identify antibody 
cross-reactivity between coronavirus species and immunogenic epitopes responsible for 
eliciting an antibody response. 
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Using multiple sequence alignment, coronavirus N-protein homologues have been 
shown to be poorly conserved, with the highest homology between HCoV-NL63 and HCoV-
229E. However, these N-proteins all share the same function i.e. formation of the 
ribonucleocapsid core. We therefore aligned the regions of the N-protein homologues which 
have been experimentally proven to mediate these interactions to identify if these regions were 
more highly conserved. We, however, found that these regions are even less conserved than 
that of the full length N-protein homologues. Two highly conserved regions between all ten 
coronavirus homologues- FYYLGTGPH (at the N-terminal) and a SR rich motif – were 
identified. The region FYYLGTGPH may be responsible for mediating RNA binding, as the 
N-terminal has no other identified, specific function. The SR rich motif may be responsible for 
mediating N-N homotypic interactions, as shown by other reports. 
Since the sequence homology between the coronavirus N-homologues was shown to 
be relatively low, even at regions known to mediate certain interactions, the order/disorder 
state of the N-protein was studied. Disordered regions of a protein have no fixed tertiary 
structure, thereby allowing access to binding sites. These regions have previously been shown 
to mediate protein-protein and protein-RNA/DNA interactions. Using the VSL1 and VLXT 
algorithms of PONDR, the N-protein of HCoV-NL63 was shown to be different to other 
coronavirus N-proteins, with regard to the order/disordered state. Majority of coronavirus N-
proteins have been shown to have a structurally disordered N- and C-terminal with a third 
disordered region located in the middle. The N-protein of HCoV-NL63, however, has only one 
disordered region located in the middle of the protein. Using the SARS-CoV N-protein as a 
model, we showed with bioinformatic analysis that the majority of interactions the protein is 
understood to be involved in occur within these disordered regions. If disorder is essential for 
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mediating these interactions, the middle disordered region located between residues 109-248 
of the HCoV-NL63 N-protein should form the hub of these interactions for HCoV-NL63. In 
this study, it was shown that the N-protein is highly phosphorylated, particularly at serine 
residues, and is also highly immunogenic. These sites of phosphorylation and increased 
immunogenicity have also been shown to preferentially occur within disordered regions. 
To further characterize the N-protein, in an in vitro model, we have cloned and 
expressed the N-protein of SARS-CoV and HCoV-NL63. Using the viral RNA as a template, 
RT-PCR was used to generate cDNA of the HCoV-NL63 genome. The N-gene of HCoV-
NL63 (N1) and SARS-CoV, as well as truncated mutants corresponding to the N- (N2) and C-
terminal (N3) and the middle disordered region (N4) of the HCoV-NL63 N-protein, were PCR 
amplified and ligated into the pGEM
®
 T-easy vector for sequencing. Once sequences were 
confirmed using M13 primers the genes were removed by SgfI and PmeI enzyme restriction. 
These enzymes allow for cloning into the Flexi
TM 
protein expression vector. The Flexi
TM 
vector appends a GST affinity tag to the N-terminal of the protein to facilitate detection and 
purification and was used to genetically transform the KRX strain of competent E. coli, which 
served as the protein expression model. 
Transformed cells were grown in an LB culture and protein expression was induced 
with the addition of 0.1% rhamnose after an OD600 of 0.4 was reached. Cultures were 
subsequently harvested by centrifugation and heterologously expressed proteins were 
extracted by sonication. Protein detection by western blot analysis against the GST affinity tag 
proved that the Flexi
TM
/KRX system is a good model for the expression of the N-protein and 
generation of truncated clones. Several drawbacks were, however, encountered. These 
drawbacks include (1) the inability to express the N4 construct, most likely due to the 
 
 
 
 
Chapter 5 
118 
 
disordered nature of this region, (2) a high level of uninduced, background expression, which 
puts the cell under unnecessary stress in the logarithmic phase of growth and thereby reduces 
final yield, and (3) a high level of expressed proteins inserting into the insoluble cell fraction, 
making purification difficult. Utilizing several techniques known to increase protein solubility, 
we found the introduction of lysozymes into the lysis buffer to be the most effective in 
increasing protein solubility from the membrane bound cell fraction. 
These heterologously expressed proteins were subsequently purified using a 
glutathione resin or MagneGST
TM
 purification system and can now serve the basis of several 
post-expression studies. Future studies out of the scope of this dissertation will include 
identifying the regions involved in dimerization and RNA binding, production of antibodies in 
a murine model and identifying cytokines produced in response to infection. We have 
developed an antibody capture ELISA using the recombinantly expressed proteins to identify 
antibody cross-reactivity between coronavirus species and to identify the region of the N-
protein responsible for eliciting an immune response. 
Using a cohort of 15 patients who had previously been infected with HCoV-NL63 we 
identified that the N-protein is 100% sensitive in detecting anti-N-IgG serum antibodies but 
only 46.7% specific as the N-protein of SARS-CoV was also able to detect these antibodies. 
We found a positive control in the form of rabbit-anti-N-IgG generated against a peptide in the 
N-terminal of the N-protein to be highly sensitive and specific. It has been shown that 
antibodies generated in animals against smaller immunogenic peptides to be more sensitive 
and specific compared to the full length protein. Identifying the immunogenic peptide of the 
N-protein would therefore pose beneficial prior to the production of antibodies in a murine 
model. Both the N- and C-terminal of the N-protein were, however, equally sensitive in 
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detecting these serum antibodies, therefore indicating the presence of several immunogenic 
peptides dispersed along the entire length of the HCoV-NL63 N-protein, or the division of one 
immunogenic peptide between the N- and C-terminal. Inclusion of the middle disordered 
region would therefore serve highly beneficial in characterizing the immunogenicity of the N-
protein. 
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Appendix 1: Sequence verification of the cloned SARS N-gene in pGEM. Cloned genes were sequenced with M13 
forward and reverse primers. M13 primer binding sites are located up- and down-stream of the multiple cloning site 
allowing for easy sequencing (Data applies to appendix 1-5). The sequencing polymerase is only capable of sequencing 
±800bp and therefore sequencing of the entire fragment is not possible, which accounts for the large amount of gaps and 
mismatch at respective ends (Data applies to appendix 1 and 2). SARS_N_F represents the gene strand sequenced with M13 
forward primers, where the SARS_N_R represents the gene strand sequenced with M13 reverse primers. SARS_N_FL is the 
sequence of the SARS N-gene obtained from NCBI with accession number AY360146.1. 
 
 
 
 
Appendix 
138 
 
 
 
Appendix 2: Sequence verification of the cloned full length HCoV-NL63 N-gene in pGEM®. NL63_N_R represents the 
gene strand sequenced with M13 reverse primers, where the NL63_N_F represents the gene strand sequenced with M13 
forward primers. NL63_N_FL is the sequence of the NL63 N-gene obtained from NCBI with accession number DQ846901.1. 
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Appendix 3: Sequence verification of the cloned 5’ half (N2: 1-567bp) of the HCoV-NL63 N-gene in pGEM®. N2_R 
represents the gene strand sequenced with M13 reverse primers, where the N2_F represents the gene strand sequenced with 
M13 forward primers. N2_FL is the sequence of the 5’ half (N2) of the HCoV-NL63 N-gene obtained from NCBI with 
accession number DQ846901.1. 
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Appendix 4: Sequence verification of the cloned 3’ half (N2: 568-1134bp) of the HCoV-NL63 N-gene in pGEM®. N3_R 
represents the gene strand sequenced with M13 reverse primers, where the N3_F represents the gene strand sequenced with 
M13 forward primers. N3_FL is the sequence of the 3’ half (N3) of the HCoV-NL63 N-gene obtained from NCBI with 
accession number DQ846901.1. 
 
 
 
Appendix 5: Sequence verification of the cloned middle region (N4: 379-756bp) of the HCoV-NL63 N-gene in pGEM. 
N4_R represents the gene strand sequenced with M13 reverse primers, where the N4_F represents the gene strand sequenced 
with M13 forward primers. N4_FL is the sequence of the middle region (N4) of the HCoV-NL63 N-gene obtained from 
NCBI with accession number DQ846901.1. 
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Appendix 6: Sequence verification of the cloned SARS N-gene. Cloned genes were sequenced with the T7 terminator 
primer. T7 primer sites lie downstream of the cloning site and upstream of the GST fusion tag sequence. As the polymerase 
can only read ±800bp into the sequence, the forward primer is not suitable as only the GST gene would be sequenced (Data is 
relevant for appendix 1-5). SARS_FL represents the sequence for the SARS N-gene obtained from NCBI with accession 
number AY360146.1, where SARS represents the sequence of the cloned SARS N-gene. 
 
 
 
 
 
 
 
Appendix 
142 
 
 
 
Appendix 7: Sequence verification of the HCoV-NL63 full length N-gene. NL63_FL represents the sequence for the 
HCoV-NL63 N-gene obtained from NCBI with accession number DQ846901.1, where N1 represents the sequence of the 
cloned HCoV-NL63 N-gene. 
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Appendix 8: Sequence verification of the 5’ (1-567bp) half of the HCoV-NL63 N-gene coding for the N-terminal half 
(N2) of the HCoV-NL63 N-protein. N2_FL represents the sequence for the 5’ half of the HCoV-NL63 N-gene obtained 
from NCBI with accession number DQ846901.1, where N2 represents the sequence of the cloned N2-gene. 
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Appendix 9: Sequence verification of the 3’ (568-1134bp) half of the HCoV-NL63 N-gene coding for the C-terminal 
half (N3) of the HCoV-NL63 N-protein. N3_FL represents the sequence for the 3’ half of the HCoV-NL63 N-gene obtained 
from NCBI with accession number DQ846901.1, where N3 represents the sequence of the cloned N3-gene. 
 
 
 
Appendix 10: Sequence verification of the middle region (379-756bp) of the HCoV-NL63 N-gene coding for the middle 
region (N4) of the HCoV-NL63 N-protein. N4_FL represents the sequence for the middle region of the HCoV-NL63 N-
gene obtained from NCBI with accession number DQ846901.1, where N4 represents the sequence of the cloned N4-gene. 
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Appendix 11: Sequencing vector pGEM®-T Easy vector. 
 
 
Appendix 12: Bacterial protein expression vector, pFN2A Flexi™. 
 
 
 
 
